Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher. REACH-2 was a randomised, doub...
Saved in:
| Published in: | The lancet oncology Vol. 20; no. 2; pp. 282 - 296 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Elsevier Ltd
01.02.2019
Elsevier Limited Elsevier |
| Subjects: | |
| ISSN: | 1470-2045, 1474-5488, 1474-5488 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher.
REACH-2 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 92 hospitals, clinics, and medical centres in 20 countries. Eligible patients were aged 18 years or older and had histologically or cytologically confirmed hepatocellular carcinoma, or diagnosed cirrhosis and hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage B or C disease, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group (ECOG) performance statuses of 0 or 1, α-fetoprotein concentrations of 400 ng/mL or greater, and had previously received first-line sorafenib. Participants were randomly assigned (2:1) via an interactive web response system with a computer-generated random sequence to 8 mg/kg intravenous ramucirumab every 2 weeks or placebo. All patients received best supportive care. The primary endpoint was overall survival. Secondary endpoints were progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), and time to deterioration in ECOG performance status. We also pooled individual patient data from REACH-2 with data from REACH (NCT01140347) for patients with α-fetoprotein concentrations of 400 ng/mL or greater. Efficacy analyses were by intention to treat, whereas safety analyses were done in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02435433.
Between July 26, 2015, and Aug 30, 2017, 292 patients were randomly assigned, 197 to the ramucirumab group and 95 to the placebo group. At a median follow-up of 7·6 months (IQR 4·0–12·5), median overall survival (8·5 months [95% CI 7·0–10·6] vs 7·3 months [5·4–9·1]; hazard ratio [HR] 0·710 [95% CI 0·531–0·949]; p=0·0199) and progression-free survival (2·8 months [2·8–4·1] vs 1·6 months [1·5–2·7]; 0·452 [0·339–0·603]; p<0·0001) were significantly improved in the ramucirumab group compared with the placebo group. The proportion of patients with an objective response did not differ significantly between groups (nine [5%] of 197 vs one [1%] of 95; p=0·1697). Median time to deterioration in FHSI-8 total scores (3·7 months [95% CI 2·8–4·4] vs 2·8 months [1·6–2·9]; HR 0·799 [95% CI 0·545–1·171]; p=0·238) and ECOG performance statuses (HR 1·082 [95% CI 0·639–1·832]; p=0·77) did not differ between groups. Grade 3 or worse treatment-emergent adverse events that occurred in at least 5% of patients in either group were hypertension (25 [13%] in the ramucirumab group vs five [5%] in the placebo group), hyponatraemia (11 [6%] vs 0) and increased aspartate aminotransferase (six [3%] vs five [5%]). Serious adverse events of any grade and cause occurred in 68 (35%) patients in the ramucirumab group and 28 (29%) patients in the placebo group. Three patients in the ramucirumab group died from treatment-emergent adverse events that were judged to be related to study treatment (one had acute kidney injury, one had hepatorenal syndrome, and one had renal failure).
REACH-2 met its primary endpoint, showing improved overall survival for ramucirumab compared with placebo in patients with hepatocellular carcinoma and α-fetoprotein concentrations of at least 400 ng/mL who had previously received sorafenib. Ramucirumab was well tolerated, with a manageable safety profile. To our knowledge, REACH-2 is the first positive phase 3 trial done in a biomarker-selected patient population with hepatocellular carcinoma.
Eli Lilly. |
|---|---|
| AbstractList | Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher.
REACH-2 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 92 hospitals, clinics, and medical centres in 20 countries. Eligible patients were aged 18 years or older and had histologically or cytologically confirmed hepatocellular carcinoma, or diagnosed cirrhosis and hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage B or C disease, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group (ECOG) performance statuses of 0 or 1, α-fetoprotein concentrations of 400 ng/mL or greater, and had previously received first-line sorafenib. Participants were randomly assigned (2:1) via an interactive web response system with a computer-generated random sequence to 8 mg/kg intravenous ramucirumab every 2 weeks or placebo. All patients received best supportive care. The primary endpoint was overall survival. Secondary endpoints were progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), and time to deterioration in ECOG performance status. We also pooled individual patient data from REACH-2 with data from REACH (NCT01140347) for patients with α-fetoprotein concentrations of 400 ng/mL or greater. Efficacy analyses were by intention to treat, whereas safety analyses were done in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02435433.
Between July 26, 2015, and Aug 30, 2017, 292 patients were randomly assigned, 197 to the ramucirumab group and 95 to the placebo group. At a median follow-up of 7·6 months (IQR 4·0–12·5), median overall survival (8·5 months [95% CI 7·0–10·6] vs 7·3 months [5·4–9·1]; hazard ratio [HR] 0·710 [95% CI 0·531–0·949]; p=0·0199) and progression-free survival (2·8 months [2·8–4·1] vs 1·6 months [1·5–2·7]; 0·452 [0·339–0·603]; p<0·0001) were significantly improved in the ramucirumab group compared with the placebo group. The proportion of patients with an objective response did not differ significantly between groups (nine [5%] of 197 vs one [1%] of 95; p=0·1697). Median time to deterioration in FHSI-8 total scores (3·7 months [95% CI 2·8–4·4] vs 2·8 months [1·6–2·9]; HR 0·799 [95% CI 0·545–1·171]; p=0·238) and ECOG performance statuses (HR 1·082 [95% CI 0·639–1·832]; p=0·77) did not differ between groups. Grade 3 or worse treatment-emergent adverse events that occurred in at least 5% of patients in either group were hypertension (25 [13%] in the ramucirumab group vs five [5%] in the placebo group), hyponatraemia (11 [6%] vs 0) and increased aspartate aminotransferase (six [3%] vs five [5%]). Serious adverse events of any grade and cause occurred in 68 (35%) patients in the ramucirumab group and 28 (29%) patients in the placebo group. Three patients in the ramucirumab group died from treatment-emergent adverse events that were judged to be related to study treatment (one had acute kidney injury, one had hepatorenal syndrome, and one had renal failure).
REACH-2 met its primary endpoint, showing improved overall survival for ramucirumab compared with placebo in patients with hepatocellular carcinoma and α-fetoprotein concentrations of at least 400 ng/mL who had previously received sorafenib. Ramucirumab was well tolerated, with a manageable safety profile. To our knowledge, REACH-2 is the first positive phase 3 trial done in a biomarker-selected patient population with hepatocellular carcinoma.
Eli Lilly. Summary Background Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher. Methods REACH-2 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 92 hospitals, clinics, and medical centres in 20 countries. Eligible patients were aged 18 years or older and had histologically or cytologically confirmed hepatocellular carcinoma, or diagnosed cirrhosis and hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage B or C disease, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group (ECOG) performance statuses of 0 or 1, α-fetoprotein concentrations of 400 ng/mL or greater, and had previously received first-line sorafenib. Participants were randomly assigned (2:1) via an interactive web response system with a computer-generated random sequence to 8 mg/kg intravenous ramucirumab every 2 weeks or placebo. All patients received best supportive care. The primary endpoint was overall survival. Secondary endpoints were progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), and time to deterioration in ECOG performance status. We also pooled individual patient data from REACH-2 with data from REACH (NCT01140347) for patients with α-fetoprotein concentrations of 400 ng/mL or greater. Efficacy analyses were by intention to treat, whereas safety analyses were done in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02435433. Findings Between July 26, 2015, and Aug 30, 2017, 292 patients were randomly assigned, 197 to the ramucirumab group and 95 to the placebo group. At a median follow-up of 7·6 months (IQR 4·0–12·5), median overall survival (8·5 months [95% CI 7·0–10·6] vs 7·3 months [5·4–9·1]; hazard ratio [HR] 0·710 [95% CI 0·531–0·949]; p=0·0199) and progression-free survival (2·8 months [2·8–4·1] vs 1·6 months [1·5–2·7]; 0·452 [0·339–0·603]; p<0·0001) were significantly improved in the ramucirumab group compared with the placebo group. The proportion of patients with an objective response did not differ significantly between groups (nine [5%] of 197 vs one [1%] of 95; p=0·1697). Median time to deterioration in FHSI-8 total scores (3·7 months [95% CI 2·8–4·4] vs 2·8 months [1·6–2·9]; HR 0·799 [95% CI 0·545–1·171]; p=0·238) and ECOG performance statuses (HR 1·082 [95% CI 0·639–1·832]; p=0·77) did not differ between groups. Grade 3 or worse treatment-emergent adverse events that occurred in at least 5% of patients in either group were hypertension (25 [13%] in the ramucirumab group vs five [5%] in the placebo group), hyponatraemia (11 [6%] vs 0) and increased aspartate aminotransferase (six [3%] vs five [5%]). Serious adverse events of any grade and cause occurred in 68 (35%) patients in the ramucirumab group and 28 (29%) patients in the placebo group. Three patients in the ramucirumab group died from treatment-emergent adverse events that were judged to be related to study treatment (one had acute kidney injury, one had hepatorenal syndrome, and one had renal failure). Interpretation REACH-2 met its primary endpoint, showing improved overall survival for ramucirumab compared with placebo in patients with hepatocellular carcinoma and α-fetoprotein concentrations of at least 400 ng/mL who had previously received sorafenib. Ramucirumab was well tolerated, with a manageable safety profile. To our knowledge, REACH-2 is the first positive phase 3 trial done in a biomarker-selected patient population with hepatocellular carcinoma. Funding Eli Lilly. Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher. Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher.BACKGROUNDPatients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher.REACH-2 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 92 hospitals, clinics, and medical centres in 20 countries. Eligible patients were aged 18 years or older and had histologically or cytologically confirmed hepatocellular carcinoma, or diagnosed cirrhosis and hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage B or C disease, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group (ECOG) performance statuses of 0 or 1, α-fetoprotein concentrations of 400 ng/mL or greater, and had previously received first-line sorafenib. Participants were randomly assigned (2:1) via an interactive web response system with a computer-generated random sequence to 8 mg/kg intravenous ramucirumab every 2 weeks or placebo. All patients received best supportive care. The primary endpoint was overall survival. Secondary endpoints were progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), and time to deterioration in ECOG performance status. We also pooled individual patient data from REACH-2 with data from REACH (NCT01140347) for patients with α-fetoprotein concentrations of 400 ng/mL or greater. Efficacy analyses were by intention to treat, whereas safety analyses were done in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02435433.METHODSREACH-2 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 92 hospitals, clinics, and medical centres in 20 countries. Eligible patients were aged 18 years or older and had histologically or cytologically confirmed hepatocellular carcinoma, or diagnosed cirrhosis and hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage B or C disease, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group (ECOG) performance statuses of 0 or 1, α-fetoprotein concentrations of 400 ng/mL or greater, and had previously received first-line sorafenib. Participants were randomly assigned (2:1) via an interactive web response system with a computer-generated random sequence to 8 mg/kg intravenous ramucirumab every 2 weeks or placebo. All patients received best supportive care. The primary endpoint was overall survival. Secondary endpoints were progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), and time to deterioration in ECOG performance status. We also pooled individual patient data from REACH-2 with data from REACH (NCT01140347) for patients with α-fetoprotein concentrations of 400 ng/mL or greater. Efficacy analyses were by intention to treat, whereas safety analyses were done in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02435433.Between July 26, 2015, and Aug 30, 2017, 292 patients were randomly assigned, 197 to the ramucirumab group and 95 to the placebo group. At a median follow-up of 7·6 months (IQR 4·0-12·5), median overall survival (8·5 months [95% CI 7·0-10·6] vs 7·3 months [5·4-9·1]; hazard ratio [HR] 0·710 [95% CI 0·531-0·949]; p=0·0199) and progression-free survival (2·8 months [2·8-4·1] vs 1·6 months [1·5-2·7]; 0·452 [0·339-0·603]; p<0·0001) were significantly improved in the ramucirumab group compared with the placebo group. The proportion of patients with an objective response did not differ significantly between groups (nine [5%] of 197 vs one [1%] of 95; p=0·1697). Median time to deterioration in FHSI-8 total scores (3·7 months [95% CI 2·8-4·4] vs 2·8 months [1·6-2·9]; HR 0·799 [95% CI 0·545-1·171]; p=0·238) and ECOG performance statuses (HR 1·082 [95% CI 0·639-1·832]; p=0·77) did not differ between groups. Grade 3 or worse treatment-emergent adverse events that occurred in at least 5% of patients in either group were hypertension (25 [13%] in the ramucirumab group vs five [5%] in the placebo group), hyponatraemia (11 [6%] vs 0) and increased aspartate aminotransferase (six [3%] vs five [5%]). Serious adverse events of any grade and cause occurred in 68 (35%) patients in the ramucirumab group and 28 (29%) patients in the placebo group. Three patients in the ramucirumab group died from treatment-emergent adverse events that were judged to be related to study treatment (one had acute kidney injury, one had hepatorenal syndrome, and one had renal failure).FINDINGSBetween July 26, 2015, and Aug 30, 2017, 292 patients were randomly assigned, 197 to the ramucirumab group and 95 to the placebo group. At a median follow-up of 7·6 months (IQR 4·0-12·5), median overall survival (8·5 months [95% CI 7·0-10·6] vs 7·3 months [5·4-9·1]; hazard ratio [HR] 0·710 [95% CI 0·531-0·949]; p=0·0199) and progression-free survival (2·8 months [2·8-4·1] vs 1·6 months [1·5-2·7]; 0·452 [0·339-0·603]; p<0·0001) were significantly improved in the ramucirumab group compared with the placebo group. The proportion of patients with an objective response did not differ significantly between groups (nine [5%] of 197 vs one [1%] of 95; p=0·1697). Median time to deterioration in FHSI-8 total scores (3·7 months [95% CI 2·8-4·4] vs 2·8 months [1·6-2·9]; HR 0·799 [95% CI 0·545-1·171]; p=0·238) and ECOG performance statuses (HR 1·082 [95% CI 0·639-1·832]; p=0·77) did not differ between groups. Grade 3 or worse treatment-emergent adverse events that occurred in at least 5% of patients in either group were hypertension (25 [13%] in the ramucirumab group vs five [5%] in the placebo group), hyponatraemia (11 [6%] vs 0) and increased aspartate aminotransferase (six [3%] vs five [5%]). Serious adverse events of any grade and cause occurred in 68 (35%) patients in the ramucirumab group and 28 (29%) patients in the placebo group. Three patients in the ramucirumab group died from treatment-emergent adverse events that were judged to be related to study treatment (one had acute kidney injury, one had hepatorenal syndrome, and one had renal failure).REACH-2 met its primary endpoint, showing improved overall survival for ramucirumab compared with placebo in patients with hepatocellular carcinoma and α-fetoprotein concentrations of at least 400 ng/mL who had previously received sorafenib. Ramucirumab was well tolerated, with a manageable safety profile. To our knowledge, REACH-2 is the first positive phase 3 trial done in a biomarker-selected patient population with hepatocellular carcinoma.INTERPRETATIONREACH-2 met its primary endpoint, showing improved overall survival for ramucirumab compared with placebo in patients with hepatocellular carcinoma and α-fetoprotein concentrations of at least 400 ng/mL who had previously received sorafenib. Ramucirumab was well tolerated, with a manageable safety profile. To our knowledge, REACH-2 is the first positive phase 3 trial done in a biomarker-selected patient population with hepatocellular carcinoma.Eli Lilly.FUNDINGEli Lilly. |
| Author | Yen, Chia-Jui Zhu, Andrew X Pracht, Marc Kudo, Masatoshi Rau, Kun-Ming Galle, Peter R Daniele, Bruno Morimoto, Manabu Ohno, Izumi Lim, Ho Yeong Hsu, Yanzhi Llovet, Josep M Motomura, Kenta Abada, Paolo B Assenat, Eric Shin, Dong Bok Hiriart, Jean-Baptiste Merle, Philippe Gerken, Guido Borg, Christophe Kang, Yoon-Koo Brandi, Giovanni Finn, Richard S Okusaka, Takuji |
| Author_xml | – sequence: 1 givenname: Andrew X surname: Zhu fullname: Zhu, Andrew X email: azhu@mgh.harvard.edu organization: Massachusetts General Hospital Cancer Center, Harvard Medical Center, Boston, MA, USA – sequence: 2 givenname: Yoon-Koo surname: Kang fullname: Kang, Yoon-Koo organization: Asan Medical Center, University of Ulsan, Seoul, South Korea – sequence: 3 givenname: Chia-Jui surname: Yen fullname: Yen, Chia-Jui organization: Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital Tainan, Taiwan – sequence: 4 givenname: Richard S surname: Finn fullname: Finn, Richard S organization: Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA – sequence: 5 givenname: Peter R surname: Galle fullname: Galle, Peter R organization: University Medical Center, Mainz, Germany – sequence: 6 givenname: Josep M surname: Llovet fullname: Llovet, Josep M organization: Icahn School of Medicine at Mount Sinai, New York, NY, USA – sequence: 7 givenname: Eric surname: Assenat fullname: Assenat, Eric organization: CHU de Montpellier, Montpellier, France – sequence: 8 givenname: Giovanni surname: Brandi fullname: Brandi, Giovanni organization: University Hospital S Orsola, Bologna, Italy – sequence: 9 givenname: Marc surname: Pracht fullname: Pracht, Marc organization: Centre Eugene Marquis, Rennes, France – sequence: 10 givenname: Ho Yeong surname: Lim fullname: Lim, Ho Yeong organization: Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea – sequence: 11 givenname: Kun-Ming surname: Rau fullname: Rau, Kun-Ming organization: Chang Gung Memorial Hospital—Kaohsiung Branch, Kaohsiung City, Taiwan – sequence: 12 givenname: Kenta surname: Motomura fullname: Motomura, Kenta organization: Aso Iizuka Hospital—Hepatology, Iizuka, Fukuoka, Japan – sequence: 13 givenname: Izumi surname: Ohno fullname: Ohno, Izumi organization: National Cancer Center Hospital East—Hepatobiliary and Pancreatic Oncology, Kashiwa, Chiba, Japan – sequence: 14 givenname: Philippe surname: Merle fullname: Merle, Philippe organization: Hôpital de la Croix Rousse, Lyon, France – sequence: 15 givenname: Bruno surname: Daniele fullname: Daniele, Bruno organization: Azienda Ospedaliera G Rummo, Benevento, Benevento, Italy – sequence: 16 givenname: Dong Bok surname: Shin fullname: Shin, Dong Bok organization: Gachon University Gil Medical Center, Incheon, South Korea – sequence: 17 givenname: Guido surname: Gerken fullname: Gerken, Guido organization: Universtitätsklinikum Essen AöR, Essen, North Rhine-Westphalia, Germany – sequence: 18 givenname: Christophe surname: Borg fullname: Borg, Christophe organization: University Hospital of Besançon, Besançon, France – sequence: 19 givenname: Jean-Baptiste surname: Hiriart fullname: Hiriart, Jean-Baptiste organization: CHU de Bordeaux, Pessac, France – sequence: 20 givenname: Takuji surname: Okusaka fullname: Okusaka, Takuji organization: National Cancer Center Hospital, Tokyo, Japan – sequence: 21 givenname: Manabu surname: Morimoto fullname: Morimoto, Manabu organization: Kanagawa Cancer Center, Yokohama, Kanagawa, Japan – sequence: 22 givenname: Yanzhi surname: Hsu fullname: Hsu, Yanzhi organization: Eli Lilly, New York, NY, USA – sequence: 23 givenname: Paolo B surname: Abada fullname: Abada, Paolo B organization: Eli Lilly, Indianapolis, IN, USA – sequence: 24 givenname: Masatoshi surname: Kudo fullname: Kudo, Masatoshi organization: Kindai University, Osaka-Sayama, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30665869$$D View this record in MEDLINE/PubMed https://hal.umontpellier.fr/hal-02927464$$DView record in HAL |
| BookMark | eNqNks1u1DAUhSNURH_gEUCW2MxIBOzYSWwQQqOqUKSRkAqsLcdxNC4ee2o7g_pYPAN7nombmdLFbMoqyc13jn3vPafFkQ_eFMVzgl8TTJo3XwlrcVlhVs8In1MsaFuKR8UJlFlZM86Pdu975Lg4TekaY9ISXD8pjilumpo34qT4faXWo7ZxXKsOqSGbiFKIajDedsh6tFHZGp8T-mnzCql-q7w2PVoZ-BG0cW50KiKtorY-rBVSvgeZjkYlwP78KgeTwyaGbMBMBxD7HMEz-IRmVxeL88uymr9FCkVQhrUF1SvUh7Fzpuyc9fC1cUqbLpSgzjE4NxGbFfgjinK0yj0tHg_KJfPs7nlWfP948Q2cl18-fT5fLEvNOMml4lWNaSPqvqN0YIrytqk7zig1gmNadUS3lArGaq6ajpJeDLRntR5gjINoO3pWzPe-K-XkJtq1ircyKCsvF0s51XAlqpY1bEuAne1Z6P1mNClL6G2al_ImjElWpBWUcyFqQF8eoNdhjB46mSjWwq0rDNSLO2rs1qa_P__fKgGo94COIaVohnuEYDlFRu4iI6c8SMLlLjJy0r070GmbdxuCRVn3oPrDXm1g8FtrokwaAgMZsdHoLPtgH3R4f-CgYe9WK_fD3P6H_i969u6O |
| CitedBy_id | crossref_primary_10_1007_s00535_020_01753_0 crossref_primary_10_1007_s00535_020_01668_w crossref_primary_10_1097_JS9_0000000000000652 crossref_primary_10_3389_fimmu_2024_1463655 crossref_primary_10_2147_JHC_S447578 crossref_primary_10_3892_mmr_2025_13474 crossref_primary_10_1002_jgh3_12573 crossref_primary_10_2174_1874467215666220103111009 crossref_primary_10_1186_s12951_023_01776_8 crossref_primary_10_1007_s00280_020_04223_9 crossref_primary_10_1016_j_jddst_2022_103905 crossref_primary_10_2147_JHC_S341195 crossref_primary_10_1016_j_drudis_2021_02_001 crossref_primary_10_1055_a_2189_6353 crossref_primary_10_1016_j_jvir_2020_07_009 crossref_primary_10_2217_hep_2021_0011 crossref_primary_10_1016_j_cgh_2023_01_039 crossref_primary_10_1111_apt_70090 crossref_primary_10_3390_cancers13194882 crossref_primary_10_3390_cancers14061526 crossref_primary_10_1016_j_ejca_2020_06_007 crossref_primary_10_1016_j_annonc_2023_12_008 crossref_primary_10_1111_liv_14157 crossref_primary_10_1002_cam4_5145 crossref_primary_10_1111_liv_15487 crossref_primary_10_3390_cancers14102381 crossref_primary_10_2147_TCRM_S420371 crossref_primary_10_1002_hep_32527 crossref_primary_10_3390_cancers13081962 crossref_primary_10_3389_fonc_2022_950266 crossref_primary_10_1200_OP_25_00253 crossref_primary_10_1007_s00280_020_04116_x crossref_primary_10_1016_j_aohep_2022_100740 crossref_primary_10_3390_livers3010011 crossref_primary_10_1136_jitc_2020_001033 crossref_primary_10_3389_fimmu_2023_1229560 crossref_primary_10_3389_fonc_2022_814120 crossref_primary_10_1111_hepr_13358 crossref_primary_10_3389_fonc_2022_1016952 crossref_primary_10_2147_JHC_S449540 crossref_primary_10_1016_j_critrevonc_2020_103167 crossref_primary_10_3390_cancers16112034 crossref_primary_10_1016_j_jhep_2021_09_035 crossref_primary_10_3350_cmh_2019_0049n crossref_primary_10_1111_hepr_13597 crossref_primary_10_1016_j_jhep_2019_03_002 crossref_primary_10_1007_s10637_019_00881_6 crossref_primary_10_1007_s40203_024_00285_2 crossref_primary_10_1111_apt_15245 crossref_primary_10_3389_fonc_2020_580241 crossref_primary_10_1016_S2468_1253_24_00247_4 crossref_primary_10_1038_s41575_024_01024_w crossref_primary_10_1016_j_drup_2024_101084 crossref_primary_10_1186_s40425_019_0824_5 crossref_primary_10_2147_JHC_S412446 crossref_primary_10_1007_s11938_021_00346_x crossref_primary_10_1016_j_jhep_2019_11_006 crossref_primary_10_3390_ijms23158305 crossref_primary_10_1016_j_critrevonc_2020_103179 crossref_primary_10_1111_hepr_13588 crossref_primary_10_2174_0929867327666200422143847 crossref_primary_10_1007_s00761_022_01113_y crossref_primary_10_1016_S0140_6736_22_01200_4 crossref_primary_10_1007_s40266_021_00871_5 crossref_primary_10_1016_j_jfma_2024_01_031 crossref_primary_10_1016_j_jceh_2021_04_003 crossref_primary_10_1016_j_jss_2019_07_077 crossref_primary_10_3389_fonc_2022_1040812 crossref_primary_10_1007_s12672_025_03363_9 crossref_primary_10_2147_JHC_S399135 crossref_primary_10_1016_j_biopha_2024_117059 crossref_primary_10_20960_revcancer_00102 crossref_primary_10_1007_s43472_021_00042_2 crossref_primary_10_3390_cells13131102 crossref_primary_10_3390_ijms21165840 crossref_primary_10_1159_000526638 crossref_primary_10_1007_s00432_021_03602_w crossref_primary_10_3390_cancers14092056 crossref_primary_10_1002_hep_31466 crossref_primary_10_1159_000542285 crossref_primary_10_3389_fonc_2024_1363695 crossref_primary_10_1159_000530079 crossref_primary_10_3390_cancers12123830 crossref_primary_10_1136_gutjnl_2020_321702 crossref_primary_10_1080_14712598_2024_2363234 crossref_primary_10_1111_liv_15052 crossref_primary_10_1159_000542291 crossref_primary_10_3390_cancers12061668 crossref_primary_10_3390_cancers12030754 crossref_primary_10_1002_jhbp_1408 crossref_primary_10_1007_s10147_022_02174_0 crossref_primary_10_1016_j_ejca_2023_113248 crossref_primary_10_3390_cancers13225665 crossref_primary_10_1016_j_hbpd_2022_08_003 crossref_primary_10_1016_j_ejca_2023_05_021 crossref_primary_10_1080_01635581_2022_2049322 crossref_primary_10_1016_j_isci_2024_111657 crossref_primary_10_1158_1078_0432_CCR_21_3548 crossref_primary_10_4251_wjgo_v13_i12_2038 crossref_primary_10_1097_TP_0000000000004425 crossref_primary_10_1159_000532023 crossref_primary_10_3390_ijms24032805 crossref_primary_10_1186_s12951_022_01615_2 crossref_primary_10_3390_curroncol32090490 crossref_primary_10_1002_1878_0261_12980 crossref_primary_10_1002_kjm2_12303 crossref_primary_10_1200_OP_24_00872 crossref_primary_10_3390_cancers12082132 crossref_primary_10_3390_vaccines8040616 crossref_primary_10_2147_JHC_S357313 crossref_primary_10_1007_s11523_021_00834_1 crossref_primary_10_1007_s00261_021_03074_z crossref_primary_10_1016_j_canlet_2023_216192 crossref_primary_10_1053_j_gastro_2021_12_276 crossref_primary_10_3390_cancers11101517 crossref_primary_10_1053_j_gastro_2021_12_275 crossref_primary_10_2147_JHC_S323302 crossref_primary_10_1007_s12072_025_10875_7 crossref_primary_10_1038_s41388_023_02646_1 crossref_primary_10_1186_s12885_021_08124_9 crossref_primary_10_1186_s12876_023_02674_x crossref_primary_10_1007_s12072_022_10392_x crossref_primary_10_1186_s12885_023_11298_z crossref_primary_10_1159_000538815 crossref_primary_10_3389_fimmu_2023_1150985 crossref_primary_10_1080_14737140_2023_2183844 crossref_primary_10_1016_j_jhep_2021_09_007 crossref_primary_10_3390_reports4030025 crossref_primary_10_1007_s12072_025_10799_2 crossref_primary_10_1016_j_ejca_2023_05_008 crossref_primary_10_1002_cld_1058 crossref_primary_10_3390_ijms25041996 crossref_primary_10_1055_a_2189_8567 crossref_primary_10_1177_17588359221148029 crossref_primary_10_2217_hep_2021_0003 crossref_primary_10_1007_s11894_022_00842_9 crossref_primary_10_1080_14712598_2020_1749593 crossref_primary_10_3390_app11041882 crossref_primary_10_1097_HEP_0000000000000893 crossref_primary_10_2217_fon_2020_0758 crossref_primary_10_1002_cam4_3116 crossref_primary_10_2217_hep_2020_0004 crossref_primary_10_12998_wjcc_v9_i21_5754 crossref_primary_10_1016_j_critrevonc_2025_104842 crossref_primary_10_3390_ph14010028 crossref_primary_10_1007_s00535_025_02233_z crossref_primary_10_1159_000530028 crossref_primary_10_3390_ijms21176302 crossref_primary_10_1002_hep4_1481 crossref_primary_10_1038_s41598_025_14759_6 crossref_primary_10_1097_MD_0000000000021191 crossref_primary_10_3390_biomedicines11041020 crossref_primary_10_3390_cancers13112708 crossref_primary_10_3390_ijms22115801 crossref_primary_10_1371_journal_pone_0321189 crossref_primary_10_5306_wjco_v15_i11_1394 crossref_primary_10_1055_a_1226_3047 crossref_primary_10_1080_17474124_2022_2150841 crossref_primary_10_3389_fmolb_2021_635243 crossref_primary_10_1007_s12029_021_00759_y crossref_primary_10_3390_ph14010036 crossref_primary_10_2147_OTT_S383685 crossref_primary_10_3390_cancers15092506 crossref_primary_10_1016_j_dld_2020_10_005 crossref_primary_10_3390_biomedicines9101345 crossref_primary_10_4251_wjgo_v14_i9_1622 crossref_primary_10_1097_MOG_0000000000000626 crossref_primary_10_1245_s10434_021_09974_0 crossref_primary_10_1002_onco_13638 crossref_primary_10_1016_j_biopha_2024_116783 crossref_primary_10_1186_s12575_025_00281_6 crossref_primary_10_1002_cam4_4468 crossref_primary_10_3390_cancers12102906 crossref_primary_10_3390_ph14010043 crossref_primary_10_1111_jcmm_15852 crossref_primary_10_1038_s41388_020_01519_1 crossref_primary_10_1016_j_bbcan_2025_189323 crossref_primary_10_3390_cancers15174223 crossref_primary_10_1055_a_2460_6298 crossref_primary_10_1007_s00330_022_08643_4 crossref_primary_10_1016_j_annonc_2021_02_014 crossref_primary_10_1055_a_2026_1277 crossref_primary_10_1080_13543784_2022_2022121 crossref_primary_10_1158_1078_0432_CCR_21_3135 crossref_primary_10_1016_j_soc_2023_06_008 crossref_primary_10_1016_j_jhep_2022_01_018 crossref_primary_10_3390_cancers13246337 crossref_primary_10_1080_13543784_2022_2017879 crossref_primary_10_1016_j_neo_2021_11_011 crossref_primary_10_1002_cam4_3389 crossref_primary_10_3389_fimmu_2025_1594577 crossref_primary_10_1007_s00262_022_03185_6 crossref_primary_10_1016_j_jhep_2019_05_014 crossref_primary_10_21276_apalm_3362 crossref_primary_10_1111_liv_14533 crossref_primary_10_3389_fonc_2024_1405178 crossref_primary_10_20960_revcancer_00116 crossref_primary_10_3390_cancers14163971 crossref_primary_10_3390_ijms241411799 crossref_primary_10_1007_s11010_022_04483_4 crossref_primary_10_1007_s12072_020_10073_7 crossref_primary_10_1007_s00280_022_04428_0 crossref_primary_10_2147_JHC_S364703 crossref_primary_10_3389_fphar_2022_1026337 crossref_primary_10_3390_cancers16223829 crossref_primary_10_11569_wcjd_v33_i6_441 crossref_primary_10_3390_cancers14081975 crossref_primary_10_1007_s11377_022_00636_5 crossref_primary_10_1002_advs_202105631 crossref_primary_10_1016_j_ijbiomac_2023_125513 crossref_primary_10_1158_1078_0432_CCR_21_4000 crossref_primary_10_1111_liv_15434 crossref_primary_10_1111_liv_14584 crossref_primary_10_1002_jgh3_12772 crossref_primary_10_1080_14737140_2021_1948329 crossref_primary_10_1016_j_jhep_2021_07_004 crossref_primary_10_1016_j_cld_2024_08_011 crossref_primary_10_1158_0008_5472_CAN_19_0803 crossref_primary_10_1080_14656566_2021_1953473 crossref_primary_10_1016_j_clinre_2020_101590 crossref_primary_10_1159_000531317 crossref_primary_10_3389_fonc_2021_737767 crossref_primary_10_3389_fonc_2023_1267870 crossref_primary_10_1002_cbf_3913 crossref_primary_10_1016_j_clcc_2020_05_007 crossref_primary_10_3389_fonc_2021_635731 crossref_primary_10_1007_s40487_021_00154_4 crossref_primary_10_1093_jnci_djaa119 crossref_primary_10_1136_bmjopen_2023_077903 crossref_primary_10_1002_ijc_33898 crossref_primary_10_1007_s15015_019_0102_x crossref_primary_10_1111_liv_14113 crossref_primary_10_3389_fonc_2022_821903 crossref_primary_10_1111_liv_15685 crossref_primary_10_3390_life13101987 crossref_primary_10_1055_a_2026_1240 crossref_primary_10_1159_000501501 crossref_primary_10_2147_JHC_S195570 crossref_primary_10_2196_17082 crossref_primary_10_1080_14728214_2022_2083107 crossref_primary_10_3390_ijms23052801 crossref_primary_10_1016_j_medcle_2020_09_004 crossref_primary_10_1038_s41416_023_02334_7 crossref_primary_10_1093_oncolo_oyad090 crossref_primary_10_1080_17512433_2021_1958674 crossref_primary_10_1159_000507022 crossref_primary_10_3390_cancers13174444 crossref_primary_10_1080_17474124_2023_2162503 crossref_primary_10_3390_cancers11111800 crossref_primary_10_1007_s10555_023_10084_4 crossref_primary_10_1007_s12072_021_10171_0 crossref_primary_10_1186_s12876_020_01391_z crossref_primary_10_1080_13543784_2022_2079491 crossref_primary_10_1200_EDBK_430028 crossref_primary_10_1016_j_clon_2019_06_002 crossref_primary_10_1001_jamanetworkopen_2020_33761 crossref_primary_10_1186_s13046_019_1412_8 crossref_primary_10_1038_s12276_020_00527_1 crossref_primary_10_3390_cancers16050901 crossref_primary_10_3390_cancers13153740 crossref_primary_10_1371_journal_pone_0247728 crossref_primary_10_3390_jpm14040370 crossref_primary_10_3892_mco_2021_2316 crossref_primary_10_1055_s_0044_1779713 crossref_primary_10_1159_000530495 crossref_primary_10_1038_s41598_021_93794_5 crossref_primary_10_1080_14737140_2020_1712198 crossref_primary_10_14309_ajg_0000000000000843 crossref_primary_10_3390_cancers17020278 crossref_primary_10_1002_cam4_4430 crossref_primary_10_1111_liv_14573 crossref_primary_10_4240_wjgs_v14_i6_528 crossref_primary_10_1038_s41419_023_06302_0 crossref_primary_10_1002_adbi_202000030 crossref_primary_10_1001_jamanetworkopen_2022_22721 crossref_primary_10_1097_PPO_0000000000000682 crossref_primary_10_1055_a_2334_8311 crossref_primary_10_1002_cai2_60 crossref_primary_10_3390_ijms242316773 crossref_primary_10_1038_s41416_020_0737_6 crossref_primary_10_3390_cancers13153758 crossref_primary_10_1136_jitc_2022_005414 crossref_primary_10_1007_s00259_022_05920_8 crossref_primary_10_1038_s41416_021_01380_3 crossref_primary_10_1038_s43018_022_00357_2 crossref_primary_10_1097_MD_0000000000030871 crossref_primary_10_1016_j_jhep_2020_11_036 crossref_primary_10_2217_fon_2021_0083 crossref_primary_10_3390_cells10071715 crossref_primary_10_3390_jpm11111199 crossref_primary_10_1111_liv_14941 crossref_primary_10_3390_cells8060536 crossref_primary_10_1002_cpt_2919 crossref_primary_10_3390_cancers16244251 crossref_primary_10_3390_ijms252413590 crossref_primary_10_1038_s41389_020_0226_z crossref_primary_10_2147_JHC_S480958 crossref_primary_10_1177_1073274820945975 crossref_primary_10_3892_mco_2023_2625 crossref_primary_10_1097_MEG_0000000000002346 crossref_primary_10_1016_j_exger_2023_112334 crossref_primary_10_1038_s41416_021_01393_y crossref_primary_10_2147_CMAR_S216220 crossref_primary_10_3390_cancers13174334 crossref_primary_10_3390_cancers14246245 crossref_primary_10_37349_edd_2025_100588 crossref_primary_10_1016_j_dld_2020_12_001 crossref_primary_10_1016_j_jhep_2020_11_026 crossref_primary_10_1007_s00044_024_03318_9 crossref_primary_10_1016_j_yao_2024_02_001 crossref_primary_10_1038_s41416_021_01260_w crossref_primary_10_1002_cam4_3880 crossref_primary_10_1515_oncologie_2022_1019 crossref_primary_10_3390_cancers14051168 crossref_primary_10_1007_s00535_024_02150_7 crossref_primary_10_2147_JHC_S318865 crossref_primary_10_3390_ijms24032685 crossref_primary_10_2147_JHC_S454666 crossref_primary_10_1007_s11523_020_00757_3 crossref_primary_10_1038_s41421_023_00563_x crossref_primary_10_1080_14737140_2023_2181162 crossref_primary_10_2147_CMAR_S539527 crossref_primary_10_2217_hep_2023_0002 crossref_primary_10_3748_wjg_v25_i7_789 crossref_primary_10_1002_cam4_4747 crossref_primary_10_2147_JHC_S399874 crossref_primary_10_1016_j_semcancer_2022_01_005 crossref_primary_10_1186_s12876_024_03167_1 crossref_primary_10_1016_j_medcli_2020_09_022 crossref_primary_10_1007_s00432_021_03803_3 crossref_primary_10_1159_000539380 crossref_primary_10_1038_s41575_021_00438_0 crossref_primary_10_3390_ijms23073778 crossref_primary_10_1016_j_jgo_2021_06_013 crossref_primary_10_3389_fimmu_2022_1052937 crossref_primary_10_1111_ajt_15551 crossref_primary_10_1016_j_biopha_2023_115561 crossref_primary_10_1038_s41572_020_00240_3 crossref_primary_10_1097_ot9_0000000000000086 crossref_primary_10_1016_S1470_2045_20_30156_X crossref_primary_10_3390_ijms22169044 crossref_primary_10_1007_s00535_022_01893_5 crossref_primary_10_1272_manms_21_235 crossref_primary_10_1002_ctm2_233 crossref_primary_10_1002_hep4_1535 crossref_primary_10_1016_j_bj_2024_100757 crossref_primary_10_4103_jcrt_jcrt_129_25 crossref_primary_10_1053_j_gastro_2021_01_233 crossref_primary_10_3390_cancers13123091 crossref_primary_10_1136_gutjnl_2025_334928 crossref_primary_10_3390_cancers12102961 crossref_primary_10_7717_peerj_10382 crossref_primary_10_3390_cancers14194647 crossref_primary_10_3390_cancers13174387 crossref_primary_10_1007_s12328_023_01761_6 crossref_primary_10_2147_JHC_S436804 crossref_primary_10_1097_HEP_0000000000000572 crossref_primary_10_3390_ijms232214117 crossref_primary_10_1055_a_2446_2408 crossref_primary_10_2147_JHC_S316223 crossref_primary_10_1080_13543784_2019_1677606 crossref_primary_10_3390_cancers16101831 crossref_primary_10_3390_cancers13092002 crossref_primary_10_1016_j_ejca_2020_09_031 crossref_primary_10_3390_cancers15123257 crossref_primary_10_1002_onco_13819 crossref_primary_10_3390_ijms241310858 crossref_primary_10_1016_S0140_6736_25_01042_6 crossref_primary_10_3390_cancers13040651 crossref_primary_10_1111_liv_14994 crossref_primary_10_1016_j_heliyon_2024_e41346 crossref_primary_10_1007_s10238_024_01399_9 crossref_primary_10_3390_cancers15123243 crossref_primary_10_1053_j_gastro_2019_03_029 crossref_primary_10_2217_fon_2019_0287 crossref_primary_10_1159_000529574 crossref_primary_10_3390_ijms21155232 crossref_primary_10_3390_cancers11111646 crossref_primary_10_3390_cancers14122975 crossref_primary_10_4155_fmc_2022_0045 crossref_primary_10_1097_MCG_0000000000001366 crossref_primary_10_3389_fonc_2022_822507 crossref_primary_10_1007_s11864_024_01246_9 crossref_primary_10_1002_cncr_33803 crossref_primary_10_3748_wjg_v28_i42_6034 crossref_primary_10_3390_ph14010003 crossref_primary_10_3390_cells9091985 crossref_primary_10_1038_s41467_024_52700_z crossref_primary_10_1016_j_ctrv_2021_102221 crossref_primary_10_1080_13543784_2022_2033208 crossref_primary_10_2147_JHC_S358082 crossref_primary_10_3390_v14050986 crossref_primary_10_1001_jamanetworkopen_2020_24406 crossref_primary_10_4251_wjgo_v15_i3_405 crossref_primary_10_1038_s41467_025_61448_z crossref_primary_10_1007_s12072_020_10120_3 crossref_primary_10_1111_liv_14977 crossref_primary_10_1111_liv_15825 crossref_primary_10_1111_liv_14731 crossref_primary_10_1002_hep4_1577 crossref_primary_10_3390_cancers14163938 crossref_primary_10_5582_bst_2024_01228 crossref_primary_10_2147_JHC_S393286 crossref_primary_10_3390_cancers15030817 crossref_primary_10_1002_mco2_474 crossref_primary_10_1136_jitc_2023_008191 crossref_primary_10_1016_j_jhep_2019_06_001 crossref_primary_10_1080_14737159_2022_2154658 crossref_primary_10_1177_17588359211018026 crossref_primary_10_3390_cancers16132387 crossref_primary_10_1038_s41467_023_40402_x crossref_primary_10_1002_kjm2_12401 crossref_primary_10_2217_fon_2020_1290 crossref_primary_10_1080_1120009X_2021_1947022 crossref_primary_10_1155_2023_6707698 crossref_primary_10_1016_j_jgo_2019_10_007 crossref_primary_10_3748_wjg_v29_i10_1407 crossref_primary_10_1080_14737159_2019_1638254 crossref_primary_10_4251_wjgo_v17_i2_99612 crossref_primary_10_1016_j_nbt_2024_08_506 crossref_primary_10_3390_cancers13123041 crossref_primary_10_1016_S2468_1253_19_30040_8 crossref_primary_10_1097_MEG_0000000000002982 crossref_primary_10_1053_j_gastro_2019_05_001 crossref_primary_10_1097_LVT_0000000000000398 crossref_primary_10_1159_000525582 crossref_primary_10_1055_s_0041_1735631 crossref_primary_10_3390_cancers13123026 crossref_primary_10_1016_j_ultrasmedbio_2024_01_007 crossref_primary_10_1016_j_ejmech_2022_114376 crossref_primary_10_3390_cancers15061798 crossref_primary_10_1016_j_dld_2021_08_008 crossref_primary_10_3389_fonc_2021_801379 crossref_primary_10_3390_ph18081160 crossref_primary_10_1055_a_2242_7543 crossref_primary_10_1111_hepr_13638 crossref_primary_10_1136_bmjopen_2021_059779 crossref_primary_10_3390_biomedicines10123202 crossref_primary_10_3389_fbioe_2025_1673134 crossref_primary_10_1016_j_jhep_2019_08_017 crossref_primary_10_1016_j_jhep_2019_08_015 crossref_primary_10_1002_cam4_4900 crossref_primary_10_3390_cancers15225343 crossref_primary_10_1097_MD_0000000000027082 crossref_primary_10_1080_2162402X_2020_1824863 crossref_primary_10_1038_s41598_023_48068_7 crossref_primary_10_1016_j_bbcan_2020_188391 crossref_primary_10_4254_wjh_v11_i9_678 crossref_primary_10_1111_liv_15183 crossref_primary_10_3390_biomedicines10061304 crossref_primary_10_1038_s41575_023_00754_7 crossref_primary_10_1111_liv_15180 crossref_primary_10_1186_s13046_021_01940_8 crossref_primary_10_1007_s11845_024_03611_x crossref_primary_10_1186_s13244_022_01354_w crossref_primary_10_1016_j_intimp_2020_106222 crossref_primary_10_1016_j_jlb_2023_100009 crossref_primary_10_3389_fonc_2023_1198118 crossref_primary_10_2217_hep_2019_0001 crossref_primary_10_1038_s41575_022_00704_9 crossref_primary_10_1051_fopen_2021003 crossref_primary_10_1159_000541622 crossref_primary_10_3390_ijms25179286 crossref_primary_10_1097_HEP_0000000000001054 crossref_primary_10_3390_cancers14030621 crossref_primary_10_1002_hep4_1927 crossref_primary_10_1186_s12885_025_14092_1 crossref_primary_10_1007_s10238_025_01698_9 crossref_primary_10_1007_s12072_024_10732_z crossref_primary_10_1002_hep_30889 crossref_primary_10_2147_JHC_S404424 crossref_primary_10_2147_POR_S397972 crossref_primary_10_1159_000503302 crossref_primary_10_2147_JHC_S284440 crossref_primary_10_3390_jcm13092612 crossref_primary_10_1016_j_drup_2020_100702 crossref_primary_10_1111_hepr_13693 crossref_primary_10_1007_s40265_020_01361_5 crossref_primary_10_1038_s41575_019_0238_3 crossref_primary_10_3748_wjg_v31_i7_101672 crossref_primary_10_1002_jhbp_1135 crossref_primary_10_1007_s10637_024_01441_3 crossref_primary_10_3390_biomedicines10092277 crossref_primary_10_1007_s40261_021_01063_0 crossref_primary_10_1186_s12885_022_10271_6 crossref_primary_10_3390_cancers15215118 crossref_primary_10_3390_ph14030233 crossref_primary_10_1016_j_jhep_2021_04_047 crossref_primary_10_1016_j_cels_2020_07_006 crossref_primary_10_1093_jjco_hyaf017 crossref_primary_10_1007_s11523_023_01029_6 crossref_primary_10_1007_s40265_020_01263_6 crossref_primary_10_1111_jgh_15475 crossref_primary_10_1016_j_jhep_2019_09_010 crossref_primary_10_1002_jgh3_70033 crossref_primary_10_1097_MD_0000000000027013 crossref_primary_10_3390_cancers15215131 crossref_primary_10_4254_wjh_v12_i12_1349 crossref_primary_10_1007_s10637_021_01185_4 crossref_primary_10_1055_a_1190_5681 crossref_primary_10_1186_s43556_024_00184_0 crossref_primary_10_2147_DDDT_S304857 crossref_primary_10_1159_000508809 crossref_primary_10_1016_j_dld_2023_10_028 crossref_primary_10_3390_cells10040869 crossref_primary_10_1158_1078_0432_CCR_20_3094 crossref_primary_10_1159_000540969 crossref_primary_10_2147_JHC_S251729 crossref_primary_10_3390_ijms26094077 crossref_primary_10_1007_s12072_024_10741_y crossref_primary_10_3748_wjg_v27_i24_3429 crossref_primary_10_1016_j_jhep_2019_09_026 crossref_primary_10_3390_cancers12030684 crossref_primary_10_1007_s10147_022_02166_0 crossref_primary_10_1002_hep_32613 crossref_primary_10_1177_17562848211016959 crossref_primary_10_1111_ajco_13768 crossref_primary_10_2217_fon_2021_0905 crossref_primary_10_1007_s41971_020_00080_8 crossref_primary_10_1038_s41392_024_02075_w crossref_primary_10_1177_17588359231225040 crossref_primary_10_1007_s11912_021_01099_7 crossref_primary_10_4251_wjgo_v15_i10_1796 crossref_primary_10_1111_hepr_13669 crossref_primary_10_1016_j_jvir_2024_02_017 crossref_primary_10_1007_s13577_023_00967_7 crossref_primary_10_1159_000507934 crossref_primary_10_1038_s41392_024_02097_4 crossref_primary_10_2147_JHC_S294440 crossref_primary_10_1016_j_jceh_2025_102547 crossref_primary_10_1016_j_aohep_2025_101905 crossref_primary_10_1158_2159_8290_CD_20_1408 crossref_primary_10_3390_cancers15225378 crossref_primary_10_2147_JHC_S285735 crossref_primary_10_1080_2162402X_2019_1615817 crossref_primary_10_1016_S1470_2045_19_30165_2 crossref_primary_10_5306_wjco_v13_i6_448 crossref_primary_10_1007_s10585_022_10188_1 crossref_primary_10_3390_cancers13133248 crossref_primary_10_1016_j_medj_2021_03_002 crossref_primary_10_3390_cancers15225406 crossref_primary_10_1007_s00535_023_01985_w crossref_primary_10_3389_fimmu_2023_1210802 crossref_primary_10_3389_fonc_2022_1094104 crossref_primary_10_1016_j_jhep_2025_08_018 crossref_primary_10_1016_j_cld_2020_07_001 crossref_primary_10_1002_hsr2_147 crossref_primary_10_1159_000533493 crossref_primary_10_3389_fphar_2025_1671001 crossref_primary_10_1002_hep_31306 crossref_primary_10_3390_ijms231911030 crossref_primary_10_7759_cureus_77867 crossref_primary_10_1016_j_ejca_2022_02_009 crossref_primary_10_1158_1078_0432_CCR_19_1858 crossref_primary_10_1097_LVT_0000000000000550 crossref_primary_10_1038_s41392_024_02072_z crossref_primary_10_3390_cancers12103049 crossref_primary_10_1136_jitc_2021_002794 crossref_primary_10_3390_cancers12103048 crossref_primary_10_3389_fimmu_2023_1046771 crossref_primary_10_1016_j_cld_2020_07_012 crossref_primary_10_1038_s41575_019_0229_4 crossref_primary_10_1002_jgh3_12691 crossref_primary_10_1186_s13046_021_02016_3 crossref_primary_10_3390_cancers12082026 crossref_primary_10_3390_cancers15112950 crossref_primary_10_1111_apt_15573 crossref_primary_10_1016_j_cld_2020_07_008 crossref_primary_10_4251_wjgo_v14_i8_1510 crossref_primary_10_1016_j_jfma_2020_10_031 crossref_primary_10_1016_j_cld_2020_07_004 crossref_primary_10_1007_s11605_023_05783_w crossref_primary_10_1038_s41575_021_00465_x crossref_primary_10_1007_s12672_024_01558_0 crossref_primary_10_1007_s15015_022_3910_3 crossref_primary_10_2147_JHC_S380439 crossref_primary_10_1159_000546574 crossref_primary_10_3390_ijms241713274 crossref_primary_10_3389_fimmu_2024_1418965 crossref_primary_10_3389_fcell_2022_1089124 crossref_primary_10_3748_wjg_v30_i19_2512 crossref_primary_10_3390_biomedicines10112827 crossref_primary_10_1186_s40364_025_00774_2 crossref_primary_10_3390_cancers14215173 crossref_primary_10_3748_wjg_v29_i17_2571 crossref_primary_10_1002_lt_26264 crossref_primary_10_1002_cam4_6369 crossref_primary_10_1097_COC_0000000000000754 crossref_primary_10_1002_cam4_6124 crossref_primary_10_1016_j_jhep_2020_07_026 crossref_primary_10_1200_GO_23_00159 crossref_primary_10_3390_cancers12113078 crossref_primary_10_1007_s10637_019_00760_0 crossref_primary_10_1080_17474124_2021_1842732 crossref_primary_10_1111_jgh_16225 crossref_primary_10_1002_hep_31327 crossref_primary_10_1002_jbt_23719 crossref_primary_10_3390_cancers11101433 crossref_primary_10_3390_cancers13020213 crossref_primary_10_1016_j_cgh_2024_03_028 crossref_primary_10_1111_hepr_13460 crossref_primary_10_1136_gutjnl_2023_331695 crossref_primary_10_3389_fonc_2022_948293 crossref_primary_10_3390_app11041598 crossref_primary_10_3390_ijms242216484 crossref_primary_10_3390_jpm12020149 crossref_primary_10_1016_j_iliver_2025_100187 crossref_primary_10_1093_ajhp_zxaa365 crossref_primary_10_3390_cancers12103025 crossref_primary_10_1007_s00262_021_03060_w crossref_primary_10_1055_s_0041_1722932 crossref_primary_10_3390_cancers12082045 crossref_primary_10_3390_cancers13184719 crossref_primary_10_1371_journal_pone_0244370 crossref_primary_10_1111_liv_14496 crossref_primary_10_1111_liv_15101 crossref_primary_10_12688_f1000research_24543_1 crossref_primary_10_3390_biom10010117 crossref_primary_10_1016_j_ejca_2022_11_017 crossref_primary_10_1159_000534304 crossref_primary_10_3389_fimmu_2023_1245708 crossref_primary_10_1111_apt_15789 crossref_primary_10_1002_cam4_4367 crossref_primary_10_1186_s40364_021_00319_3 crossref_primary_10_1159_000544101 crossref_primary_10_1002_cnr2_1679 crossref_primary_10_2147_JHC_S365002 crossref_primary_10_3390_pharmaceutics14040804 crossref_primary_10_1016_j_ejmech_2023_115420 crossref_primary_10_1002_ueg2_12111 crossref_primary_10_2147_JHC_S289840 crossref_primary_10_1634_theoncologist_2020_0521 crossref_primary_10_3390_cancers13020238 crossref_primary_10_3390_cancers16050850 crossref_primary_10_1055_a_2189_8461 crossref_primary_10_4254_wjh_v17_i8_107873 crossref_primary_10_1080_13543784_2022_2151891 crossref_primary_10_1007_s10396_022_01260_0 crossref_primary_10_2147_JHC_S220978 crossref_primary_10_1016_j_seminoncol_2025_152369 crossref_primary_10_1080_14737140_2019_1674141 crossref_primary_10_1016_S1470_2045_19_30009_9 crossref_primary_10_2217_cer_2020_0236 crossref_primary_10_1002_hep_32447 crossref_primary_10_1186_s12885_023_11166_w crossref_primary_10_1007_s00535_024_02202_y crossref_primary_10_3390_cancers13112621 crossref_primary_10_3390_cimb46060356 crossref_primary_10_2147_JHC_S318070 crossref_primary_10_3389_fimmu_2022_1060051 crossref_primary_10_1016_j_jhep_2021_01_046 crossref_primary_10_3390_app10134607 crossref_primary_10_1007_s12254_020_00590_4 crossref_primary_10_1177_1758835920970840 crossref_primary_10_1007_s10930_024_10211_2 crossref_primary_10_1016_j_jhep_2025_08_042 crossref_primary_10_1177_17562848221086126 crossref_primary_10_1007_s10456_019_09698_6 crossref_primary_10_3390_cancers15204977 crossref_primary_10_1080_14712598_2022_2013799 crossref_primary_10_1186_s12967_022_03249_2 crossref_primary_10_1016_j_aohep_2022_100677 crossref_primary_10_1016_j_jhep_2023_03_003 crossref_primary_10_3389_fimmu_2025_1533874 crossref_primary_10_3390_ijms26052192 crossref_primary_10_3390_cancers13112608 crossref_primary_10_1007_s10637_022_01248_0 crossref_primary_10_1016_j_seminoncol_2025_152348 crossref_primary_10_3389_fimmu_2020_01986 crossref_primary_10_1158_1078_0432_CCR_21_3208 crossref_primary_10_2147_JHC_S393964 crossref_primary_10_1038_s41575_019_0186_y crossref_primary_10_3390_cancers16233944 crossref_primary_10_3389_fimmu_2022_896752 crossref_primary_10_1016_j_soc_2019_06_015 crossref_primary_10_1200_EDBK_237555 crossref_primary_10_1200_OP_25_00198 crossref_primary_10_3390_cells9092027 crossref_primary_10_1007_s00535_021_01773_4 crossref_primary_10_2147_JHC_S383922 crossref_primary_10_3390_jcm10122662 crossref_primary_10_3390_healthcare10020218 crossref_primary_10_1080_03007995_2021_1940908 crossref_primary_10_1159_000502905 crossref_primary_10_2147_JHC_S311496 crossref_primary_10_4329_wjr_v16_i10_512 crossref_primary_10_4155_bio_2020_0199 crossref_primary_10_3748_wjg_v27_i26_4104 crossref_primary_10_1080_21655979_2021_1950261 crossref_primary_10_1080_14656566_2021_1892074 crossref_primary_10_1159_000507370 crossref_primary_10_1038_s41392_020_00264_x crossref_primary_10_1038_s41575_019_0240_9 crossref_primary_10_1080_13543784_2022_2072726 crossref_primary_10_1002_hep_31165 crossref_primary_10_4254_wjh_v14_i6_1074 crossref_primary_10_2147_JHC_S268310 crossref_primary_10_3389_fimmu_2023_1298290 crossref_primary_10_1186_s40164_024_00539_x crossref_primary_10_1097_TP_0000000000002955 crossref_primary_10_1016_j_ejso_2020_03_210 crossref_primary_10_48165_gjs_2025_2102 crossref_primary_10_1007_s15036_021_2311_3 crossref_primary_10_1016_j_jprot_2020_103834 crossref_primary_10_2147_JHC_S268314 crossref_primary_10_1038_s41598_021_98937_2 crossref_primary_10_1200_JCO_24_00533 crossref_primary_10_3390_cancers15092624 crossref_primary_10_1016_S1470_2045_21_00409_5 crossref_primary_10_3389_fonc_2021_667669 crossref_primary_10_3390_cancers14194553 crossref_primary_10_1093_jjco_hyab108 crossref_primary_10_1002_hep_31175 crossref_primary_10_3390_cancers12092495 crossref_primary_10_1111_liv_14405 crossref_primary_10_3390_cancers16183150 crossref_primary_10_1007_s12328_021_01434_2 crossref_primary_10_1007_s11901_019_00491_z crossref_primary_10_1007_s10637_019_00801_8 crossref_primary_10_1007_s12325_022_02371_3 crossref_primary_10_1007_s10637_021_01090_w crossref_primary_10_3389_fphar_2023_1301202 crossref_primary_10_3389_fimmu_2021_652172 crossref_primary_10_3389_fonc_2024_1432423 crossref_primary_10_3390_cancers15174345 crossref_primary_10_1186_s13046_022_02436_9 crossref_primary_10_1002_cncr_32076 crossref_primary_10_1038_s41598_024_53709_6 crossref_primary_10_1136_gutjnl_2019_320282 crossref_primary_10_2147_OTT_S268309 crossref_primary_10_1007_s12072_024_10728_9 crossref_primary_10_1021_acsbiomaterials_5c00218 crossref_primary_10_2147_CMAR_S547885 crossref_primary_10_3390_cancers14010232 crossref_primary_10_1111_hepr_14158 crossref_primary_10_3390_jcm9092682 crossref_primary_10_1016_j_ultrasmedbio_2024_05_003 crossref_primary_10_1080_17425255_2023_2272598 crossref_primary_10_1080_14737159_2024_2392278 crossref_primary_10_1016_j_annonc_2025_02_006 crossref_primary_10_1159_000531671 crossref_primary_10_1016_j_jbiotec_2024_09_003 crossref_primary_10_5500_wjt_v10_i11_297 crossref_primary_10_1016_j_jhepr_2025_101571 crossref_primary_10_1007_s10238_023_01014_3 crossref_primary_10_1200_GO_20_00425 crossref_primary_10_1158_1078_0432_CCR_22_0569 crossref_primary_10_1186_s12885_024_12000_7 crossref_primary_10_1007_s10637_020_00977_4 crossref_primary_10_1016_j_hbpd_2021_04_004 crossref_primary_10_1002_onco_13776 crossref_primary_10_3390_cells10082096 crossref_primary_10_1111_liv_14223 crossref_primary_10_1007_s44446_025_00001_x crossref_primary_10_1038_s41423_020_00572_w crossref_primary_10_1038_s41575_019_0179_x crossref_primary_10_1038_s41467_022_34249_x crossref_primary_10_3390_cancers13184584 crossref_primary_10_3390_cancers11060861 crossref_primary_10_1016_j_critrevonc_2023_104191 crossref_primary_10_1159_000508485 crossref_primary_10_3390_biomedicines11020468 crossref_primary_10_1371_journal_pone_0265235 crossref_primary_10_2147_JHC_S224938 crossref_primary_10_1007_s40273_019_00839_9 crossref_primary_10_1007_s44178_025_00179_z crossref_primary_10_1159_000502714 crossref_primary_10_3390_cancers11060873 crossref_primary_10_3390_ijms25189853 crossref_primary_10_1038_s41401_020_0478_3 crossref_primary_10_1007_s00108_019_00722_x crossref_primary_10_3390_cancers17010101 crossref_primary_10_1002_jgh3_12408 crossref_primary_10_1007_s40801_023_00379_x crossref_primary_10_1159_000541018 crossref_primary_10_2217_bmm_2020_0474 crossref_primary_10_3389_fonc_2022_993948 crossref_primary_10_3390_ijms22041931 crossref_primary_10_1002_onco_13550 crossref_primary_10_1016_j_jdiacomp_2024_108688 crossref_primary_10_1002_cnr2_1613 crossref_primary_10_1038_s41571_023_00816_4 crossref_primary_10_1097_HC9_0000000000000302 crossref_primary_10_1055_a_1557_6864 crossref_primary_10_1186_s12935_022_02682_z crossref_primary_10_1159_000509554 crossref_primary_10_3389_fonc_2022_898964 crossref_primary_10_2147_CLEP_S431498 crossref_primary_10_1016_j_jfma_2021_08_018 crossref_primary_10_3390_cancers15010023 crossref_primary_10_1007_s12672_023_00708_0 crossref_primary_10_1111_jcmm_16875 crossref_primary_10_1007_s15004_022_8944_3 crossref_primary_10_1111_liv_14210 crossref_primary_10_1186_s40164_024_00494_7 crossref_primary_10_1002_hep4_2025 crossref_primary_10_1111_liv_14462 crossref_primary_10_1371_journal_pone_0311084 crossref_primary_10_1097_01_COT_0001097204_55713_71 crossref_primary_10_1007_s12072_024_10692_4 crossref_primary_10_1186_s12885_023_11107_7 crossref_primary_10_1007_s12072_023_10488_y crossref_primary_10_3390_cancers14235868 crossref_primary_10_1158_1078_0432_CCR_20_1690 crossref_primary_10_1097_HC9_0000000000000776 crossref_primary_10_3390_ijms26051936 crossref_primary_10_1177_17588359221097934 crossref_primary_10_1186_s12885_024_12484_3 crossref_primary_10_1080_2162402X_2023_2214478 crossref_primary_10_1111_liv_15918 crossref_primary_10_3350_cmh_2020_0096 crossref_primary_10_1007_s10637_024_01420_8 crossref_primary_10_1200_EDBK_280811 crossref_primary_10_1002_cam4_5931 crossref_primary_10_1159_000507889 crossref_primary_10_1097_MD_0000000000019958 crossref_primary_10_1007_s11901_021_00560_2 crossref_primary_10_1016_S1470_2045_20_30011_5 crossref_primary_10_3390_jcm13195925 crossref_primary_10_3748_wjg_v26_i16_1888 crossref_primary_10_3390_antiox11101929 crossref_primary_10_1016_j_bbcan_2020_188451 crossref_primary_10_1007_s00108_019_00682_2 crossref_primary_10_3390_cancers11081085 crossref_primary_10_3390_cancers12051089 crossref_primary_10_3389_fonc_2022_1021772 crossref_primary_10_4240_wjgs_v17_i9_101834 crossref_primary_10_1007_s10238_021_00727_7 crossref_primary_10_4103_JCRP_JCRP_21_21 crossref_primary_10_3390_ijms222413627 crossref_primary_10_3390_cancers14030568 crossref_primary_10_1016_j_bj_2025_100904 crossref_primary_10_5582_bst_2024_01372 crossref_primary_10_3390_biom12050645 crossref_primary_10_1007_s15036_019_0483_x crossref_primary_10_1002_hep4_1872 crossref_primary_10_2147_OTT_S279858 crossref_primary_10_1038_s41416_021_01535_2 crossref_primary_10_1002_lt_25731 crossref_primary_10_4254_wjh_v15_i1_1 crossref_primary_10_3748_wjg_v29_i11_1669 crossref_primary_10_1186_s40364_023_00535_z crossref_primary_10_1007_s11605_022_05388_9 crossref_primary_10_1080_13543784_2022_2053108 crossref_primary_10_1111_1751_2980_13332 crossref_primary_10_1038_s41591_022_01868_2 crossref_primary_10_1016_j_jtho_2020_10_004 crossref_primary_10_1097_HEP_0000000000000237 crossref_primary_10_3390_ijms231710038 crossref_primary_10_1038_s41467_024_46118_w crossref_primary_10_2147_JHC_S353956 crossref_primary_10_1016_j_hbpd_2025_09_004 crossref_primary_10_1007_s10637_025_01506_x crossref_primary_10_3390_cancers14143351 crossref_primary_10_1007_s11901_019_00489_7 crossref_primary_10_1038_s41598_025_00004_7 crossref_primary_10_1158_0008_5472_CAN_22_3551 crossref_primary_10_1007_s00117_022_00970_3 crossref_primary_10_3390_ijms26135994 crossref_primary_10_4103_JCRP_JCRP_33_21 crossref_primary_10_1016_j_jhep_2021_12_025 crossref_primary_10_3390_cancers15020390 crossref_primary_10_1016_j_pharmthera_2023_108387 crossref_primary_10_1007_s00270_022_03228_6 crossref_primary_10_2147_JHC_S396231 crossref_primary_10_3389_fimmu_2022_808101 crossref_primary_10_1016_j_envres_2023_117132 crossref_primary_10_1001_jamanetworkopen_2021_36128 crossref_primary_10_1002_hep4_1652 crossref_primary_10_1177_17588359211039928 crossref_primary_10_3390_cancers17060972 crossref_primary_10_1007_s10637_023_01349_4 crossref_primary_10_1097_CLD_0000000000000147 crossref_primary_10_2147_JHC_S224471 crossref_primary_10_1007_s00262_025_04038_8 crossref_primary_10_3390_cancers12051290 crossref_primary_10_1159_000529636 crossref_primary_10_1093_oncolo_oyac183 crossref_primary_10_1016_j_bbcan_2020_188441 crossref_primary_10_1007_s00330_023_09953_x crossref_primary_10_3390_cancers14246151 crossref_primary_10_3390_cancers13010090 crossref_primary_10_1016_j_coph_2021_07_009 crossref_primary_10_4254_wjh_v17_i7_107520 crossref_primary_10_7554_eLife_71880 crossref_primary_10_1097_HEP_0000000000000452 crossref_primary_10_1093_oncolo_oyae342 crossref_primary_10_1111_hepr_13732 crossref_primary_10_3390_cancers14143332 crossref_primary_10_1186_s12929_024_01011_y crossref_primary_10_1016_j_ijbiomac_2022_03_113 crossref_primary_10_3389_fonc_2021_780798 crossref_primary_10_1016_j_ijbiomac_2025_143616 crossref_primary_10_1186_s12943_023_01748_4 crossref_primary_10_1080_17474124_2019_1621165 crossref_primary_10_1016_j_hbpd_2022_10_006 crossref_primary_10_3390_medicina59061115 crossref_primary_10_1002_hep4_1682 crossref_primary_10_3390_ijms25021259 crossref_primary_10_1080_13543784_2022_2042253 crossref_primary_10_3348_kjr_2019_0140 crossref_primary_10_1097_HEP_0000000000000466 crossref_primary_10_1097_CAD_0000000000001071 crossref_primary_10_3390_cancers13143536 crossref_primary_10_4103_jcrt_jcrt_1861_20 crossref_primary_10_1016_j_critrevonc_2024_104522 crossref_primary_10_1007_s00259_023_06337_7 crossref_primary_10_1016_j_aohep_2020_06_003 crossref_primary_10_1016_j_bj_2024_100815 crossref_primary_10_1038_s41598_022_21582_w crossref_primary_10_3389_fonc_2021_756672 crossref_primary_10_1016_j_hbpd_2020_08_008 crossref_primary_10_1200_CCI_24_00175 crossref_primary_10_3748_wjg_v25_i27_3607 crossref_primary_10_1038_s41573_023_00671_z crossref_primary_10_2147_JHC_S327258 crossref_primary_10_1016_j_jceh_2024_101440 crossref_primary_10_1177_17588359241297085 crossref_primary_10_1158_1078_0432_CCR_19_3897 crossref_primary_10_1007_s11684_019_0728_2 crossref_primary_10_1080_14740338_2024_2441286 crossref_primary_10_3390_cancers11111769 crossref_primary_10_1007_s10147_020_01835_2 crossref_primary_10_1111_hepr_13712 crossref_primary_10_1111_hepr_13713 crossref_primary_10_1016_j_jhep_2021_11_013 crossref_primary_10_1097_CCO_0000000000000744 crossref_primary_10_1016_j_jhep_2021_11_018 crossref_primary_10_1097_MD_0000000000026471 crossref_primary_10_1080_14737159_2021_1987217 crossref_primary_10_3390_metabo14080425 crossref_primary_10_3390_cancers15215298 crossref_primary_10_3748_wjg_v28_i28_3595 crossref_primary_10_1055_s_0043_1778660 crossref_primary_10_3389_fimmu_2021_731527 crossref_primary_10_2147_JHC_S270532 crossref_primary_10_1016_j_jceh_2019_09_007 crossref_primary_10_1016_j_jfma_2022_03_017 crossref_primary_10_1158_1078_0432_CCR_19_3884 crossref_primary_10_1016_j_jhep_2021_11_021 crossref_primary_10_24060_2076_3093_2022_12_2_139_150 crossref_primary_10_3390_cancers13102484 crossref_primary_10_1038_s41598_020_75198_z crossref_primary_10_3348_kjr_2022_0822 crossref_primary_10_3390_cancers15020348 crossref_primary_10_1016_j_molmed_2019_06_007 crossref_primary_10_1007_s00432_022_04206_8 crossref_primary_10_1016_j_jhepr_2025_101509 crossref_primary_10_1007_s11654_019_0138_6 crossref_primary_10_3389_fimmu_2023_1163136 crossref_primary_10_1007_s11523_021_00797_3 crossref_primary_10_4103_sjg_SJG_477_20 crossref_primary_10_3390_cancers17172729 crossref_primary_10_1016_j_semcancer_2023_04_010 crossref_primary_10_1080_14728214_2024_2430493 crossref_primary_10_1016_j_ctrv_2023_102526 crossref_primary_10_3390_ijms23031402 crossref_primary_10_1007_s12072_022_10406_8 crossref_primary_10_1007_s10147_022_02263_0 crossref_primary_10_1016_j_jhep_2023_11_030 crossref_primary_10_1158_1541_7786_MCR_21_0348 crossref_primary_10_1002_cnr2_1471 crossref_primary_10_1080_17474124_2021_1899808 crossref_primary_10_1016_S2468_1253_22_00042_5 crossref_primary_10_1080_14740338_2022_1995353 crossref_primary_10_1002_cld_815 crossref_primary_10_1016_j_dld_2023_04_006 crossref_primary_10_1159_000525467 crossref_primary_10_1007_s15015_021_3569_1 crossref_primary_10_3892_ol_2024_14398 crossref_primary_10_3390_cancers12051243 crossref_primary_10_3390_cancers15061680 crossref_primary_10_1159_000499765 crossref_primary_10_2174_0929867327666200219142231 crossref_primary_10_13105_wjma_v8_i3_190 crossref_primary_10_1038_s41598_020_60440_5 crossref_primary_10_2217_fon_2022_0524 crossref_primary_10_1159_000506946 crossref_primary_10_7717_peerj_14891 crossref_primary_10_1186_s40170_023_00328_w crossref_primary_10_1055_a_2189_8826 crossref_primary_10_1177_1758835920927602 crossref_primary_10_3390_cancers15030719 crossref_primary_10_1186_s12865_022_00502_7 crossref_primary_10_1007_s12328_019_01077_4 crossref_primary_10_3389_fphar_2023_1150151 crossref_primary_10_3389_fonc_2024_1495321 crossref_primary_10_1016_j_tranon_2021_101153 crossref_primary_10_1186_s40364_021_00350_4 crossref_primary_10_1053_j_gastro_2021_06_008 crossref_primary_10_1002_lci2_37 crossref_primary_10_3390_ijms21218165 crossref_primary_10_1002_lci2_38 crossref_primary_10_1016_j_annonc_2019_12_001 crossref_primary_10_1097_HEP_0000000000001163 crossref_primary_10_1158_2159_8290_CD_19_0555 crossref_primary_10_1186_s12885_025_14247_0 crossref_primary_10_1136_jitc_2020_001435 crossref_primary_10_1111_hepr_13505 crossref_primary_10_1111_hepr_13748 crossref_primary_10_1055_a_1589_7568 crossref_primary_10_1158_1940_6207_CAPR_23_0311 crossref_primary_10_1371_journal_pone_0297882 crossref_primary_10_1016_S2468_1253_21_00134_5 crossref_primary_10_1016_j_transproceed_2024_05_041 crossref_primary_10_1016_j_cgh_2020_06_072 crossref_primary_10_1007_s00261_021_03100_0 crossref_primary_10_1007_s10620_020_06797_z crossref_primary_10_4251_wjgo_v11_i10_788 crossref_primary_10_1097_MEG_0000000000001734 crossref_primary_10_1007_s12328_021_01506_3 crossref_primary_10_1007_s11377_022_00666_z crossref_primary_10_1007_s11307_020_01489_6 crossref_primary_10_4240_wjgs_v14_i3_260 crossref_primary_10_1111_hepr_13746 crossref_primary_10_3390_cancers14164028 crossref_primary_10_3390_molecules25173900 crossref_primary_10_1007_s00018_019_03351_7 crossref_primary_10_1016_j_jhep_2019_01_028 crossref_primary_10_2217_fon_2020_0283 crossref_primary_10_5582_bst_2023_01322 crossref_primary_10_2217_imt_2022_0089 crossref_primary_10_3390_cancers13215295 crossref_primary_10_3390_jpm12101726 crossref_primary_10_1080_14712598_2025_2557625 crossref_primary_10_3390_cancers14030504 crossref_primary_10_3748_wjg_v28_i34_4929 crossref_primary_10_3748_wjg_v29_i10_1551 crossref_primary_10_1111_cts_70313 crossref_primary_10_1002_lci2_50 crossref_primary_10_1186_s13045_019_0794_6 crossref_primary_10_1093_carcin_bgad052 crossref_primary_10_1136_bmj_m3544 crossref_primary_10_3389_fimmu_2021_642958 crossref_primary_10_3390_diagnostics15172144 crossref_primary_10_3390_cancers17081274 crossref_primary_10_1186_s12957_025_03963_3 crossref_primary_10_2147_JHC_S390963 crossref_primary_10_3390_cancers16040766 crossref_primary_10_1007_s11864_023_01135_7 crossref_primary_10_1245_s10434_021_09949_1 crossref_primary_10_1007_s12094_024_03568_4 crossref_primary_10_1002_cam4_70814 crossref_primary_10_2147_JHC_S347932 crossref_primary_10_1016_j_dld_2023_03_005 crossref_primary_10_3389_fgene_2022_916024 crossref_primary_10_3748_wjg_v25_i25_3136 crossref_primary_10_1111_hepr_13567 crossref_primary_10_3390_ijms25031456 crossref_primary_10_3390_jpm12050738 crossref_primary_10_3390_cells9061370 crossref_primary_10_1016_j_ctarc_2021_100328 crossref_primary_10_1080_14796694_2024_2396795 crossref_primary_10_3390_cancers12051274 crossref_primary_10_3390_cancers12051275 crossref_primary_10_1016_j_ejphar_2023_175586 crossref_primary_10_1177_17588359211031141 crossref_primary_10_1016_j_jksus_2021_101812 crossref_primary_10_4254_wjh_v13_i9_1132 crossref_primary_10_3390_medicina55090526 crossref_primary_10_1038_s41392_024_02085_8 crossref_primary_10_1158_1078_0432_CCR_19_3259 crossref_primary_10_3390_cimb47040263 crossref_primary_10_1055_a_1589_7520 crossref_primary_10_1016_j_dld_2022_01_122 crossref_primary_10_3390_molecules29133002 crossref_primary_10_1097_HEP_0000000000000030 crossref_primary_10_3390_ijms22031492 crossref_primary_10_1177_1756284820932483 crossref_primary_10_1177_1758835920937422 crossref_primary_10_3390_cancers13215475 crossref_primary_10_1016_j_canlet_2024_217088 crossref_primary_10_1016_j_dld_2019_06_015 crossref_primary_10_1158_1078_0432_CCR_21_3972 crossref_primary_10_1007_s40265_023_01907_3 crossref_primary_10_1186_s12885_024_12874_7 crossref_primary_10_3390_cancers15030766 crossref_primary_10_1177_00045632221143685 crossref_primary_10_3390_ijms25158424 crossref_primary_10_1002_lci2_62 crossref_primary_10_1038_s41392_025_02249_0 crossref_primary_10_1159_000540857 crossref_primary_10_1016_j_jhep_2024_08_028 crossref_primary_10_1016_j_rgmxen_2022_01_004 crossref_primary_10_1002_lci2_60 crossref_primary_10_1007_s12328_021_01481_9 crossref_primary_10_1186_s12935_024_03600_1 crossref_primary_10_1007_s12094_024_03653_8 crossref_primary_10_1159_000537686 crossref_primary_10_1097_COC_0000000000000787 crossref_primary_10_1159_000507815 crossref_primary_10_70352_scrj_cr_25_0331 crossref_primary_10_1016_j_ccell_2024_01_007 crossref_primary_10_1080_13543784_2022_2032641 crossref_primary_10_3892_ol_2025_15206 crossref_primary_10_1055_s_0042_1748924 crossref_primary_10_2147_JHC_S268293 crossref_primary_10_5500_wjt_v14_i3_96637 crossref_primary_10_1002_hep_32740 crossref_primary_10_1016_j_jceh_2019_07_012 |
| Cites_doi | 10.1038/s41467-018-04633-7 10.1016/S1470-2045(18)30146-3 10.1007/s12032-010-9600-6 10.1158/1078-0432.CCR-15-2883 10.1016/S0885-3924(02)00422-0 10.1002/hep.29662 10.1056/NEJMoa0708857 10.1200/JCO.2009.23.7537 10.1158/1078-0432.CCR-13-1442 10.1016/j.jhep.2011.12.001 10.1016/S1089-3261(05)70158-6 10.1002/jso.24742 10.1016/S0140-6736(18)30207-1 10.1097/MEG.0b013e32835d913b 10.1016/S1470-2045(15)00050-9 10.1371/journal.pone.0118825 10.1016/j.ejca.2017.05.001 10.1002/hep.26586 10.1002/hep.510280322 10.1016/S1470-2045(08)70285-7 10.1056/NEJMoa1717002 10.1111/ijcp.12352 10.1371/journal.pone.0090929 10.1093/annonc/mdq166 10.1016/S0140-6736(16)32453-9 10.1158/1078-0432.CCR-11-2175 10.2147/JHC.S112537 10.1038/s41571-018-0073-4 10.1016/j.bpg.2014.08.002 10.1158/0008-5472.CAN-09-1089 10.1097/00004836-200012000-00007 10.1158/0008-5472.CAN-07-6013 10.1053/j.gastro.2015.05.061 10.1093/jnci/djn134 10.1016/j.ejca.2008.10.026 10.1002/cncr.10384 |
| ContentType | Journal Article |
| Copyright | 2019 Elsevier Ltd Copyright © 2019 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Feb 2019 Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2019 Elsevier Ltd – notice: Copyright © 2019 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Feb 2019 – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| CorporateAuthor | REACH-2 study investigators |
| CorporateAuthor_xml | – name: REACH-2 study investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 1XC |
| DOI | 10.1016/S1470-2045(18)30937-9 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 296 |
| ExternalDocumentID | oai:HAL:hal-02927464v1 30665869 10_1016_S1470_2045_18_30937_9 S1470204518309379 |
| Genre | Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | Eli Lilly. |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ~HD 3V. AACTN ABLVK ABYKQ AFKWA AHPSJ AJBFU AJOXV AMFUW RIG SDF ZA5 9DU AAYXX AFFHD CITATION AFCTW ALIPV CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI 7X8 PUEGO 1XC |
| ID | FETCH-LOGICAL-c481t-a82503695db33f4a38765b8433e98032b1c73394458a6b31d9f3d45cf147f97b3 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 1352 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000457634100042&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Tue Oct 14 20:35:29 EDT 2025 Sun Sep 28 12:03:26 EDT 2025 Tue Oct 07 05:39:49 EDT 2025 Thu Apr 03 07:08:08 EDT 2025 Tue Nov 18 22:33:24 EST 2025 Sat Nov 29 07:03:04 EST 2025 Fri Feb 23 02:18:58 EST 2024 Tue Oct 14 19:35:43 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | Copyright © 2019 Elsevier Ltd. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c481t-a82503695db33f4a38765b8433e98032b1c73394458a6b31d9f3d45cf147f97b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-8958-2793 0000-0003-4873-5033 0000-0001-8294-0992 0000-0002-7515-099X 0000-0003-2494-2126 0000-0003-1729-807X |
| PMID | 30665869 |
| PQID | 2174725020 |
| PQPubID | 46089 |
| PageCount | 15 |
| ParticipantIDs | hal_primary_oai_HAL_hal_02927464v1 proquest_miscellaneous_2179388995 proquest_journals_2174725020 pubmed_primary_30665869 crossref_primary_10_1016_S1470_2045_18_30937_9 crossref_citationtrail_10_1016_S1470_2045_18_30937_9 elsevier_sciencedirect_doi_10_1016_S1470_2045_18_30937_9 elsevier_clinicalkey_doi_10_1016_S1470_2045_18_30937_9 |
| PublicationCentury | 2000 |
| PublicationDate | February 2019 2019-02-00 20190201 2019-02 |
| PublicationDateYYYYMMDD | 2019-02-01 |
| PublicationDate_xml | – month: 02 year: 2019 text: February 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2019 |
| Publisher | Elsevier Ltd Elsevier Limited Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited – name: Elsevier |
| References | Reig, Rimola, Torres (bib35) 2013; 58 Lee, Huber, Stewart, Mathews, Falcon, Chintharlapalli (bib30) 2017 Hoshida, Nijman, Kobayashi (bib32) 2009; 69 Nakazawa, Hidaka, Takada (bib14) 2013; 25 Chau, Peck-Radosavljevic, Borg (bib27) 2017; 81 Shan, Huang, Xie (bib22) 2011; 28 Forner, Diaz-Gonzalez, Liccioni, Vilana (bib5) 2014; 28 Zucman-Rossi, Villanueva, Nault, Llovet (bib23) 2015; 149 bib34 Cheng, Kang, Chen (bib8) 2009; 10 Jelic, Sotiropoulos (bib24) 2010; 21 (bib31) 2012; 56 Llovet, Montal, Sia, Finn (bib1) 2018; 15 Llovet, Ricci, Mazzaferro (bib7) 2008; 359 Yamashita, Forgues, Wang (bib21) 2008; 68 Hsu, Liu, Lee (bib17) 2015; 10 Zhu, Finn, Mulcahy (bib20) 2013; 19 (bib2) 1998; 28 Bruix, Qin, Merle (bib10) 2017; 389 Zhu, Park, Ryoo (bib18) 2015; 16 Johnson (bib33) 2001; 5 Gomaa, Hashim, Waked (bib4) 2014; 9 Borzio, Dionigi, Rossini (bib3) 2018; 67 Eisenhauer, Therasse, Bogaerts (bib25) 2009; 45 Kudo, Finn, Qin (bib9) 2018; 391 Lencioni, Kudo, Ye (bib36) 2014; 68 Trojan, Waidmann (bib37) 2016; 3 Spratlin, Cohen, Eadens (bib19) 2010; 28 Llovet, Pena, Lathia (bib29) 2012; 18 Leung, Tang, Zee (bib15) 2002; 94 Yount, Cella, Webster (bib26) 2002; 24 Silva, Gorman, Berger (bib16) 2017; 116 Llovet, Di Bisceglie, Bruix (bib38) 2008; 100 Zhu, Kang, Rosmorduc (bib28) 2016; 22 Rimassa, Assenat, Peck-Radosavljevic (bib12) 2018; 19 Tangkijvanich, Anukulkarnkusol, Suwangool (bib13) 2000; 31 Abou-Alfa, Meyer, Cheng (bib11) 2018; 379 Shen, Zeng, Guo (bib6) 2018; 9 (10.1016/S1470-2045(18)30937-9_bib2) 1998; 28 Borzio (10.1016/S1470-2045(18)30937-9_bib3) 2018; 67 Nakazawa (10.1016/S1470-2045(18)30937-9_bib14) 2013; 25 Bruix (10.1016/S1470-2045(18)30937-9_bib10) 2017; 389 Leung (10.1016/S1470-2045(18)30937-9_bib15) 2002; 94 Spratlin (10.1016/S1470-2045(18)30937-9_bib19) 2010; 28 Rimassa (10.1016/S1470-2045(18)30937-9_bib12) 2018; 19 Kudo (10.1016/S1470-2045(18)30937-9_bib9) 2018; 391 Eisenhauer (10.1016/S1470-2045(18)30937-9_bib25) 2009; 45 Trojan (10.1016/S1470-2045(18)30937-9_bib37) 2016; 3 Silva (10.1016/S1470-2045(18)30937-9_bib16) 2017; 116 Chau (10.1016/S1470-2045(18)30937-9_bib27) 2017; 81 Hoshida (10.1016/S1470-2045(18)30937-9_bib32) 2009; 69 Zucman-Rossi (10.1016/S1470-2045(18)30937-9_bib23) 2015; 149 Llovet (10.1016/S1470-2045(18)30937-9_bib7) 2008; 359 Llovet (10.1016/S1470-2045(18)30937-9_bib29) 2012; 18 (10.1016/S1470-2045(18)30937-9_bib31) 2012; 56 Llovet (10.1016/S1470-2045(18)30937-9_bib1) 2018; 15 Lee (10.1016/S1470-2045(18)30937-9_bib30) 2017 Hsu (10.1016/S1470-2045(18)30937-9_bib17) 2015; 10 Yamashita (10.1016/S1470-2045(18)30937-9_bib21) 2008; 68 Lencioni (10.1016/S1470-2045(18)30937-9_bib36) 2014; 68 Zhu (10.1016/S1470-2045(18)30937-9_bib28) 2016; 22 Cheng (10.1016/S1470-2045(18)30937-9_bib8) 2009; 10 Yount (10.1016/S1470-2045(18)30937-9_bib26) 2002; 24 Jelic (10.1016/S1470-2045(18)30937-9_bib24) 2010; 21 Zhu (10.1016/S1470-2045(18)30937-9_bib18) 2015; 16 Llovet (10.1016/S1470-2045(18)30937-9_bib38) 2008; 100 Abou-Alfa (10.1016/S1470-2045(18)30937-9_bib11) 2018; 379 Shen (10.1016/S1470-2045(18)30937-9_bib6) 2018; 9 Reig (10.1016/S1470-2045(18)30937-9_bib35) 2013; 58 Gomaa (10.1016/S1470-2045(18)30937-9_bib4) 2014; 9 Forner (10.1016/S1470-2045(18)30937-9_bib5) 2014; 28 Tangkijvanich (10.1016/S1470-2045(18)30937-9_bib13) 2000; 31 Zhu (10.1016/S1470-2045(18)30937-9_bib20) 2013; 19 Johnson (10.1016/S1470-2045(18)30937-9_bib33) 2001; 5 Shan (10.1016/S1470-2045(18)30937-9_bib22) 2011; 28 30665868 - Lancet Oncol. 2019 Feb;20(2):177-179 32156118 - Chin Clin Oncol. 2020 Aug;9(4):58 31673554 - Hepatobiliary Surg Nutr. 2019 Oct;8(5):546-548 31673543 - Hepatobiliary Surg Nutr. 2019 Oct;8(5):515-518 |
| References_xml | – volume: 56 start-page: 908 year: 2012 end-page: 943 ident: bib31 article-title: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma publication-title: J Hepatol – volume: 28 start-page: 855 year: 2014 end-page: 865 ident: bib5 article-title: Prognosis prediction and staging publication-title: Best Pract Res Clin Gastroenterol – volume: 16 start-page: 859 year: 2015 end-page: 870 ident: bib18 article-title: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial publication-title: Lancet Oncol – volume: 5 start-page: 145 year: 2001 end-page: 159 ident: bib33 article-title: The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma publication-title: Clin Liver Dis – volume: 389 start-page: 56 year: 2017 end-page: 66 ident: bib10 article-title: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet – volume: 69 start-page: 7385 year: 2009 end-page: 7392 ident: bib32 article-title: Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma publication-title: Cancer Res – volume: 94 start-page: 1760 year: 2002 end-page: 1769 ident: bib15 article-title: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients publication-title: Cancer – volume: 18 start-page: 2290 year: 2012 end-page: 2300 ident: bib29 article-title: Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma publication-title: Clin CancerRes – volume: 68 start-page: 609 year: 2014 end-page: 617 ident: bib36 article-title: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis publication-title: Int J Clin Pract – volume: 68 start-page: 1451 year: 2008 end-page: 1461 ident: bib21 article-title: EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma publication-title: Cancer Res – volume: 28 start-page: 751 year: 1998 end-page: 755 ident: bib2 article-title: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators publication-title: Hepatology – volume: 28 start-page: 1012 year: 2011 end-page: 1016 ident: bib22 article-title: Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status publication-title: Med Oncol – year: 2017 ident: bib30 article-title: P-025Evaluation of AFP expression as a predictive marker for response to anti-VEGFR-2 inhibition publication-title: Ann Oncol – ident: bib34 article-title: Assessment report. Stivarga – volume: 28 start-page: 780 year: 2010 end-page: 787 ident: bib19 article-title: Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 publication-title: J Clin Oncol – volume: 15 start-page: 599 year: 2018 end-page: 616 ident: bib1 article-title: Molecular therapies and precision medicine for hepatocellular carcinoma publication-title: Nat Rev Clin Oncol – volume: 9 start-page: 2230 year: 2018 ident: bib6 article-title: Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data publication-title: Nat Commun – volume: 149 start-page: 1226 year: 2015 end-page: 1239 ident: bib23 article-title: Genetic landscape and biomarkers of hepatocellular carcinoma publication-title: Gastroenterology – volume: 58 start-page: 2023 year: 2013 end-page: 2031 ident: bib35 article-title: Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design publication-title: Hepatology – volume: 100 start-page: 698 year: 2008 end-page: 711 ident: bib38 article-title: Design and endpoints of clinical trials in hepatocellular carcinoma publication-title: J Natl Cancer Inst – volume: 67 start-page: 2215 year: 2018 end-page: 2225 ident: bib3 article-title: External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study publication-title: Hepatology – volume: 9 start-page: e90929 year: 2014 ident: bib4 article-title: Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt publication-title: PLoS One – volume: 31 start-page: 302 year: 2000 end-page: 308 ident: bib13 article-title: Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels publication-title: J Clin Gastroenterol – volume: 21 start-page: v59 year: 2010 end-page: v64 ident: bib24 article-title: Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 359 start-page: 378 year: 2008 end-page: 390 ident: bib7 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: bib25 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer – volume: 25 start-page: 683 year: 2013 end-page: 689 ident: bib14 article-title: Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib publication-title: Eur J Gastroenterol Hepatol – volume: 19 start-page: 6614 year: 2013 end-page: 6623 ident: bib20 article-title: A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer publication-title: Clin Cancer Res – volume: 379 start-page: 54 year: 2018 end-page: 63 ident: bib11 article-title: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma publication-title: N Engl J Med – volume: 3 start-page: 31 year: 2016 end-page: 36 ident: bib37 article-title: Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma publication-title: J Hepatocell Carcinoma – volume: 24 start-page: 32 year: 2002 end-page: 44 ident: bib26 article-title: Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index publication-title: J Pain Symptom Manage – volume: 19 start-page: 682 year: 2018 end-page: 693 ident: bib12 article-title: Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study publication-title: Lancet Oncol – volume: 22 start-page: 4870 year: 2016 end-page: 4879 ident: bib28 article-title: Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib with or without erlotinib in the SEARCH trial publication-title: Clin Cancer Res – volume: 81 start-page: 17 year: 2017 end-page: 25 ident: bib27 article-title: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study publication-title: Eur J Cancer – volume: 391 start-page: 1163 year: 2018 end-page: 1173 ident: bib9 article-title: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial publication-title: Lancet – volume: 10 start-page: e0118825 year: 2015 ident: bib17 article-title: Using serum alpha-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? publication-title: PLoS One – volume: 10 start-page: 25 year: 2009 end-page: 34 ident: bib8 article-title: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial publication-title: Lancet Oncol – volume: 116 start-page: 831 year: 2017 end-page: 840 ident: bib16 article-title: The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients publication-title: J Surg Oncol – volume: 9 start-page: 2230 year: 2018 ident: 10.1016/S1470-2045(18)30937-9_bib6 article-title: Dynamically prognosticating patients with hepatocellular carcinoma through survival paths mapping based on time-series data publication-title: Nat Commun doi: 10.1038/s41467-018-04633-7 – volume: 19 start-page: 682 year: 2018 ident: 10.1016/S1470-2045(18)30937-9_bib12 article-title: Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30146-3 – volume: 28 start-page: 1012 year: 2011 ident: 10.1016/S1470-2045(18)30937-9_bib22 article-title: Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status publication-title: Med Oncol doi: 10.1007/s12032-010-9600-6 – volume: 22 start-page: 4870 year: 2016 ident: 10.1016/S1470-2045(18)30937-9_bib28 article-title: Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib with or without erlotinib in the SEARCH trial publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-2883 – volume: 24 start-page: 32 year: 2002 ident: 10.1016/S1470-2045(18)30937-9_bib26 article-title: Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index publication-title: J Pain Symptom Manage doi: 10.1016/S0885-3924(02)00422-0 – volume: 67 start-page: 2215 year: 2018 ident: 10.1016/S1470-2045(18)30937-9_bib3 article-title: External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study publication-title: Hepatology doi: 10.1002/hep.29662 – volume: 359 start-page: 378 year: 2008 ident: 10.1016/S1470-2045(18)30937-9_bib7 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0708857 – volume: 28 start-page: 780 year: 2010 ident: 10.1016/S1470-2045(18)30937-9_bib19 article-title: Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.7537 – volume: 19 start-page: 6614 year: 2013 ident: 10.1016/S1470-2045(18)30937-9_bib20 article-title: A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-13-1442 – volume: 56 start-page: 908 year: 2012 ident: 10.1016/S1470-2045(18)30937-9_bib31 article-title: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2011.12.001 – volume: 5 start-page: 145 year: 2001 ident: 10.1016/S1470-2045(18)30937-9_bib33 article-title: The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma publication-title: Clin Liver Dis doi: 10.1016/S1089-3261(05)70158-6 – volume: 116 start-page: 831 year: 2017 ident: 10.1016/S1470-2045(18)30937-9_bib16 article-title: The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients publication-title: J Surg Oncol doi: 10.1002/jso.24742 – volume: 391 start-page: 1163 year: 2018 ident: 10.1016/S1470-2045(18)30937-9_bib9 article-title: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(18)30207-1 – volume: 25 start-page: 683 year: 2013 ident: 10.1016/S1470-2045(18)30937-9_bib14 article-title: Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e32835d913b – volume: 16 start-page: 859 year: 2015 ident: 10.1016/S1470-2045(18)30937-9_bib18 article-title: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00050-9 – volume: 10 start-page: e0118825 year: 2015 ident: 10.1016/S1470-2045(18)30937-9_bib17 article-title: Using serum alpha-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff? publication-title: PLoS One doi: 10.1371/journal.pone.0118825 – volume: 81 start-page: 17 year: 2017 ident: 10.1016/S1470-2045(18)30937-9_bib27 article-title: Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.05.001 – volume: 58 start-page: 2023 year: 2013 ident: 10.1016/S1470-2045(18)30937-9_bib35 article-title: Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design publication-title: Hepatology doi: 10.1002/hep.26586 – volume: 28 start-page: 751 year: 1998 ident: 10.1016/S1470-2045(18)30937-9_bib2 article-title: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators publication-title: Hepatology doi: 10.1002/hep.510280322 – volume: 10 start-page: 25 year: 2009 ident: 10.1016/S1470-2045(18)30937-9_bib8 article-title: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(08)70285-7 – volume: 379 start-page: 54 year: 2018 ident: 10.1016/S1470-2045(18)30937-9_bib11 article-title: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1717002 – volume: 68 start-page: 609 year: 2014 ident: 10.1016/S1470-2045(18)30937-9_bib36 article-title: GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis publication-title: Int J Clin Pract doi: 10.1111/ijcp.12352 – volume: 9 start-page: e90929 year: 2014 ident: 10.1016/S1470-2045(18)30937-9_bib4 article-title: Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt publication-title: PLoS One doi: 10.1371/journal.pone.0090929 – volume: 21 start-page: v59 issue: suppl 5 year: 2010 ident: 10.1016/S1470-2045(18)30937-9_bib24 article-title: Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mdq166 – volume: 389 start-page: 56 year: 2017 ident: 10.1016/S1470-2045(18)30937-9_bib10 article-title: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32453-9 – volume: 18 start-page: 2290 year: 2012 ident: 10.1016/S1470-2045(18)30937-9_bib29 article-title: Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma publication-title: Clin CancerRes doi: 10.1158/1078-0432.CCR-11-2175 – volume: 3 start-page: 31 year: 2016 ident: 10.1016/S1470-2045(18)30937-9_bib37 article-title: Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma publication-title: J Hepatocell Carcinoma doi: 10.2147/JHC.S112537 – volume: 15 start-page: 599 year: 2018 ident: 10.1016/S1470-2045(18)30937-9_bib1 article-title: Molecular therapies and precision medicine for hepatocellular carcinoma publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-018-0073-4 – volume: 28 start-page: 855 year: 2014 ident: 10.1016/S1470-2045(18)30937-9_bib5 article-title: Prognosis prediction and staging publication-title: Best Pract Res Clin Gastroenterol doi: 10.1016/j.bpg.2014.08.002 – volume: 69 start-page: 7385 year: 2009 ident: 10.1016/S1470-2045(18)30937-9_bib32 article-title: Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-1089 – volume: 31 start-page: 302 year: 2000 ident: 10.1016/S1470-2045(18)30937-9_bib13 article-title: Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels publication-title: J Clin Gastroenterol doi: 10.1097/00004836-200012000-00007 – volume: 68 start-page: 1451 year: 2008 ident: 10.1016/S1470-2045(18)30937-9_bib21 article-title: EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-6013 – volume: 149 start-page: 1226 year: 2015 ident: 10.1016/S1470-2045(18)30937-9_bib23 article-title: Genetic landscape and biomarkers of hepatocellular carcinoma publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.05.061 – year: 2017 ident: 10.1016/S1470-2045(18)30937-9_bib30 article-title: P-025Evaluation of AFP expression as a predictive marker for response to anti-VEGFR-2 inhibition publication-title: Ann Oncol – volume: 100 start-page: 698 year: 2008 ident: 10.1016/S1470-2045(18)30937-9_bib38 article-title: Design and endpoints of clinical trials in hepatocellular carcinoma publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djn134 – volume: 45 start-page: 228 year: 2009 ident: 10.1016/S1470-2045(18)30937-9_bib25 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 94 start-page: 1760 year: 2002 ident: 10.1016/S1470-2045(18)30937-9_bib15 article-title: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients publication-title: Cancer doi: 10.1002/cncr.10384 – reference: 31673543 - Hepatobiliary Surg Nutr. 2019 Oct;8(5):515-518 – reference: 32156118 - Chin Clin Oncol. 2020 Aug;9(4):58 – reference: 30665868 - Lancet Oncol. 2019 Feb;20(2):177-179 – reference: 31673554 - Hepatobiliary Surg Nutr. 2019 Oct;8(5):546-548 |
| SSID | ssj0017105 |
| Score | 2.7223523 |
| Snippet | Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of... Summary Background Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the... |
| SourceID | hal proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 282 |
| SubjectTerms | Aged Alpha-Fetoproteins / analysis Angiogenesis Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Agents - administration & dosage Aspartate aminotransferase Biomarkers Cancer Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Cirrhosis Clinical trials Double-Blind Method Double-blind studies Drug Therapy, Combination Female Hepatocellular carcinoma Humans Immunotherapy Inhibitor drugs Intravenous administration Life Sciences Liver cancer Liver cirrhosis Liver diseases Liver Neoplasms - blood Liver Neoplasms - drug therapy Liver Neoplasms - pathology Male Medical prognosis Middle Aged Monoclonal antibodies Neoplasm Staging Oncology Patients Ramucirumab Renal failure Safety Sorafenib - administration & dosage Studies Survival Targeted cancer therapy Thromboembolism Treatment Outcome |
| Title | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204518309379 https://dx.doi.org/10.1016/S1470-2045(18)30937-9 https://www.ncbi.nlm.nih.gov/pubmed/30665869 https://www.proquest.com/docview/2174725020 https://www.proquest.com/docview/2179388995 https://hal.umontpellier.fr/hal-02927464 |
| Volume | 20 |
| WOSCitedRecordID | wos000457634100042&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7X7 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7RV dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: BENPR dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 8C1 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLbYhhAv3C-FMRnEwyZh1sROYvOCytRpD6OaykV9i3yLWqlNStPuf_EbeOc3cY6TZk9jSLxYSurjNPEXny8-N0LeBk7NY8cin6ZMZEIxY13CQNmoJEl1am0IFD7PRiM5maiLdsOtbt0qt2tiWKhdZXGP_Bipcwb6Ou5_XP5gWDUKrattCY0dsheh7gY8Z-PvnRUha1wYI5H1GaZdv4rgOf7SnTyM5BGaAzOmrtNNO1N0kryOgQZNdHr_f-_hAbnXclA6aEDzkNzy5SNy53NrZX9Mfo31YmNnq81CGxqKiNMakFL4cmborKRtLtaa4iYu3XoR0ClotnWFlgB0baUWqxSV1UJTXToQQ3paQ7ffP1nh11VIEAGDWYybLNvkvTU9HA8HJ2csPvpANQU96ioAonfvqKs2Zu6ZAVoMR8GVzFSs9bSfY4_lFMannIZCJE_It9PhVxipLfbArJDRmmn4VAVtqhJnOC-E5rBMJ0YKzr2SfR6byGYco3gTqVPDI6cK7kRiC5jIQmWGPyW7ZVX654RqJY3ve-BCRgnJHRzFLkqsdsYXsUh6RGynObdtJnQsyDHPO5c3REeO6MgjmQd05KpH3ndiyyYVyE0C6RZD-TbOFVbmHJTVTYKyE2yJUENw_kX0DYC1-3-YPPxscJ7juX6s4kyk4jLqkf0tPvN2yarzK3D2yOvuZ5hjxI0ufbUJfRSX8IkOz_BZ8w50l-JoxJOpevH3wV-Su8A5VeP4vk9216uNf0Vu28v1rF4dhPcX20kWWgmtPIkOyN6n4ehi_AfFpEwm |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLa2gYAX7pfCAINA2iTMmthJbCSEKtjUaV2FxpD6ZnyLWqlNStMO8aeQ-A2885s4zm1PY7zsgcekPm7rnMvn-DvnIPSixNQ0tCRwcUxYwgTRxkYEgo2IoljFxpSJwoNkOOSjkfi4hn40uTCeVtn4xNJR29z4d-Q7HjonEK_D7rv5V-K7RvnT1aaFRqUWB-77N9iyFW_3P8DzfRmGe7vH7_uk7ipADOPBkijYE4HbFpHVlKZMUfAHkeaMUid4l4Y6MAn16aIRV7GmgRUptSwyacCSVCSawrzr6BL48cRTyJJRu8ELkooyCQO7xJd5P80Y2vnU3twK-LY_fkyIOCsWro89KfMsxFtGvr0b_9ua3UTXa4yNe5VR3EJrLruNrhzWLII76NeRmq3MZLGaKY3LJum4AEtIXTbReJLhutZsgf1LatywJPAYIvcy9ycdnrqLje_ClOUzhVVmQczD7wKG_f5JUrfMywIYMJnxeaFZXZy4wFtHuz344-H2G6ww4ASbg6E5-wrbfKWnjmiA_XBVUuV0TupMgqkfMR_D_JjistHKXfT5QpbwHtrI8sw9QFgJrl3XAdbTgnFq4Sq0QWSU1S4NWdRBrFEraepK777hyFS2lD6vjdJrowy4LLVRig563YrNq1In5wnEjc7KJo8XIo-EYHyeIG8Fa6BXAbh_EX0OxtH-Pl8cvd8bSH-vG4owYTE7CTpos7EHWbvkQp4aQwc9az-GZ-z1RmUuX5VjBOVcCFjD-5XNtV9F_SElj8XDv0_-FF3tHx8O5GB_ePAIXQN8LSqS_ybaWC5W7jG6bE6Wk2LxpPQdGH25aMP7A9bIoUM |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxELbagiouvB-BAgaB1EqYZNfeXRsJoYg2atVQVQWk3Ixfq0RKdkM2KeJnceXKnd_EeF89lXLpgeNuPE7incfn9TczCL0oMTUNLQlcHBOWMEG0sRGBYCOiKFaxMWWi8DA5OuKjkTheQz-bXBhPq2x8YumobW78O_Kuh84JxOuw101rWsTx7uDd_CvxHaT8SWvTTqNSkUP3_Rts34q3B7vwrF-G4WDv0_t9UncYIIbxYEkU7I_AhYvIakpTpij4hkhzRqkTvEdDHZiE-tTRiKtY08CKlFoWmTRgSSoSTWHedXQFxiS-bUQyajd7QVLRJ2Fgj_iS72fZQ92P7c3tgO_4o8iEiPPi4vrYEzTPQ79lFBzc-J_X7ya6XmNv3K-M5RZac9lttPmhZhfcQb9O1GxlJovVTGlcNk_HBVhI6rKJxpMM1zVoC-xfXuOGPYHHENGXuT8B8ZRebHx3piyfKawyC2Ielhcw7PcPkrplXhbGgMmMzxfN6qLFBd4-2evDHw933mCFAT_YHAzQ2VfY5is9dUTDdgCuSgqdzkmdYTD1I-ZjmB9TXDZguYs-X8oS3kMbWZ65BwgrwbXrOcCAWjBOLVyFNoiMstqlIYs6iDUqJk1dAd43IpnKlurnNVN6zZQBl6VmStFBr1uxeVUC5SKBuNFf2eT3QkSSEKQvEuStYA0AK2D3L6LPwVDa3-eLpu_3h9Lf64UiTFjMToMO2mpsQ9auupBnhtFBz9qP4Rl7vVGZy1flGEE5FwLW8H5lf-1XUX94yWPx8O-TP0WbYG9yeHB0-AhdA9gtKu7_FtpYLlbuMbpqTpeTYvGkdCMYfblsu_sDfzyp9w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ramucirumab+after+sorafenib+in+patients+with+advanced+hepatocellular+carcinoma+and+increased+%CE%B1-fetoprotein+concentrations+%28REACH-2%29%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Zhu%2C+Andrew+X&rft.au=Kang%2C+Yoon-Koo&rft.au=Yen%2C+Chia-Jui&rft.au=Finn%2C+Richard+S&rft.date=2019-02-01&rft.pub=Elsevier+Ltd&rft.issn=1470-2045&rft.eissn=1474-5488&rft.volume=20&rft.issue=2&rft.spage=282&rft.epage=296&rft_id=info:doi/10.1016%2FS1470-2045%2818%2930937-9&rft.externalDocID=S1470204518309379 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-2045&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-2045&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-2045&client=summon |